indomethacin has been researched along with Infant, Premature, Diseases in 320 studies
Indomethacin: A non-steroidal anti-inflammatory agent (NSAID) that inhibits CYCLOOXYGENASE, which is necessary for the formation of PROSTAGLANDINS and other AUTACOIDS. It also inhibits the motility of POLYMORPHONUCLEAR LEUKOCYTES.
indometacin : A member of the class of indole-3-acetic acids that is indole-3-acetic acid in which the indole ring is substituted at positions 1, 2 and 5 by p-chlorobenzoyl, methyl, and methoxy groups, respectively. A non-steroidal anti-inflammatory drug, it is used in the treatment of musculoskeletal and joint disorders including osteoarthritis, rheumatoid arthritis, gout, bursitis and tendinitis.
Infant, Premature, Diseases: Diseases that occur in PREMATURE INFANTS.
Excerpt | Relevance | Reference |
---|---|---|
"Prophylactic indomethacin reduces the risk of severe intraventricular hemorrhage (IVH) but does not reduce death or neurodevelopmental impairment (NDI) among extremely low birth weight (ELBW) infants." | 9.27 | Effect of Prophylactic Indomethacin in Extremely Low Birth Weight Infants Based on the Predicted Risk of Severe Intraventricular Hemorrhage. ( Davis, PG; Foglia, EE; Haslam, R; Roberts, RS; Schmidt, B; Stoller, JZ, 2018) |
"Postnatal indomethacin is reportedly associated with an increased incidence of necrotizing enterocolitis (NEC) in preterm infants." | 7.77 | The risk of necrotizing enterocolitis after indomethacin tocolysis. ( Holzhausen, KA; Kellogg, H; Lulic-Botica, M; Pruder, S; Salari, V; Sood, BG; Thomas, R, 2011) |
"Dexamethasone or indomethacin predisposes very low birth weight (VLBW) neonates to spontaneous intestinal perforation (SIP)." | 7.73 | Concurrent use of indomethacin and dexamethasone increases the risk of spontaneous intestinal perforation in very low birth weight neonates. ( Friedlich, P; Paquette, L; Ramanathan, R; Seri, I, 2006) |
"Sequential bleeding times were performed on 25 preterm infants receiving intravenous indomethacin for closure of the patent ductus arteriosus." | 7.67 | Prolonged bleeding time in preterm infants receiving indomethacin for patent ductus arteriosus. ( Bejar, R; Corazza, MS; Cvetnic, W; Davis, RF; Merritt, TA, 1984) |
"This is a case report of focal intestinal perforation in a premature neonate following intravenous administration of indomethacin for patent ductus arteriosus." | 7.67 | Localized intestinal perforation following intravenous indomethacin in premature infants. ( Leonard, AS; Snover, DC; Wolf, WM, 1989) |
"Within 9 months we observed intestinal perforations in three very low birth weight (VLBW) infants undergoing indomethacin treatment for symptomatic patent ductus arteriosus (sPDA)." | 7.67 | Intestinal perforation associated with indomethacin treatment in premature infants. ( Bolkenius, M; Kühl, G; Seyberth, HW; Wille, L, 1985) |
"Indomethacin has been also used in women with short cervices as well as in those with idiopathic polyhydramnios." | 5.38 | Indomethacin in pregnancy: applications and safety. ( Abou-Ghannam, G; Nassar, AH; Usta, IM, 2012) |
"The use of indomethacin to treat patent ductus arteriosus in preterm infants may either decrease the incidence of necrotizing enterocolitis by stabilizing or closing the ductus arteriosus or increase its incidence by a direct constricting effect on mesenteric blood vessels." | 5.33 | Patent ductus arteriosus, indomethacin and necrotizing enterocolitis in very low birth weight infants: a population-based study. ( Dollberg, S; Lusky, A; Reichman, B, 2005) |
"Indomethacin use has been implicated as a co-risk factor for SIP when combined with glucocorticoids, but previous evidence argued against indomethacin being an independent risk factor when used prophylactically." | 5.33 | New insights into spontaneous intestinal perforation using a national data set: (1) SIP is associated with early indomethacin exposure. ( Attridge, JT; Clark, R; Gordon, PV; Walker, MW, 2006) |
"Prophylactic indomethacin reduces the risk of severe intraventricular hemorrhage (IVH) but does not reduce death or neurodevelopmental impairment (NDI) among extremely low birth weight (ELBW) infants." | 5.27 | Effect of Prophylactic Indomethacin in Extremely Low Birth Weight Infants Based on the Predicted Risk of Severe Intraventricular Hemorrhage. ( Davis, PG; Foglia, EE; Haslam, R; Roberts, RS; Schmidt, B; Stoller, JZ, 2018) |
" In view of this and with its higher incidence of necrotizing enterocolitis, we do not recommend using prolonged low-dose indomethacin for closing the patent ductus arteriosus in very low birth weight infants." | 5.10 | Randomized trial of prolonged low-dose versus conventional-dose indomethacin for treating patent ductus arteriosus in very low birth weight infants. ( Lee, J; Leong, JY; Rajadurai, VS; Tan, KW; Wong, EH; Wong, KY, 2003) |
"Ibuprofen therapy on the third day of life is as efficacious as indomethacin for the treatment of patent ductus arteriosus in preterm infants with the respiratory distress syndrome and is significantly less likely to induce oliguria." | 5.09 | A comparison of ibuprofen and indomethacin for closure of patent ductus arteriosus. ( Degroote, K; Langhendries, JP; Lecoutere, D; Smets, K; Van de Broek, H; Van Overmeire, B; Weyler, J, 2000) |
"This historical cohort study included 45 infants born with birth weights of 1250 g or less and received indomethacin in the first 12 hours of life for intraventricular hemorrhage prevention." | 5.09 | The use of indomethacin for the prevention of intraventricular brain hemorrhage in high-risk neonates. ( Al-Alaiyan, SA; Al-Shawaf, EM; Aqeel, AY; Gamal, MH, 2000) |
"Ninety infants, with birth weights of 600 to 1250 gm, were entered into a prospective, randomized, controlled trial to receive either indomethacin, 0." | 5.08 | Prophylactic indomethacin therapy in the first twenty-four hours of life for the prevention of patent ductus arteriosus in preterm infants treated prophylactically with surfactant in the delivery room. ( Cabalka, AK; Couser, RJ; Ferrara, TB; Hoekstra, RE; Payne, NR; Schilling, CG; Wright, GB, 1996) |
"In a randomized study the effect of an early prophylactic indomethacin treatment on the incidence of the patent ductus arteriosus (PDA) in very low birth weight infants (VLBWI) and their postnatal course were investigated." | 5.06 | [Effects of early therapy with indomethacin on the manifestation of a persistent ductus arteriosus in extremely underweight premature infants]. ( Böttcher, H; Grubbe, G; Ockert, C; Ruckhäberle, KE; Vogtmann, C, 1988) |
"The impact of early prophylactic use of intravenous indomethacin on the incidence and severity of periventricular-intraventricular hemorrhage and patent ductus arteriosus in 199 oxygen-requiring premature infants (less than or equal to 1300 g birth weight) was prospectively investigated." | 5.06 | Prophylactic indomethacin for prevention of intraventricular hemorrhage in premature infants. ( Bancalari, E; Bandstra, ES; Ferrer, PL; Flynn, J; Goldberg, RN; Gregorios, JB; Montalvo, BM; Pacheco, I, 1988) |
"Antenatal indomethacin may be associated with an increased risk of periventricular leukomalacia and necrotizing enterocolitis in premature infants and therefore should be used judiciously for tocolysis." | 4.84 | Metaanalysis of the effect of antenatal indomethacin on neonatal outcomes. ( Amin, SB; Glantz, JC; Sinkin, RA, 2007) |
"Three preterm infants exposed antenatally to indomethacin developed a characteristic syndrome consisting of edema and hydrops with a bleeding disorder at birth, oliguric renal failure during the first 3 postnatal days, and acute pneumoperitoneum resulting from localized ileal perforation(s) at the end of the first week of life." | 4.77 | Oligohydramnios, renal insufficiency, and ileal perforation in preterm infants after intrauterine exposure to indomethacin. ( Coppens, M; Cuvelier, C; de Praeter, C; Dhont, M; Govaert, P; Leroy, JG; Thiery, M; Vanhaesebrouck, P, 1988) |
"To compare the incidence of medical closure of patent ductus arteriosus (PDA) and adverse events (acute renal dysfunction, necrotizing enterocolitis, spontaneous intestinal perforation, and gastrointestinal bleeding) between preterm infants who received indomethacin and ibuprofen for the treatment of PDA." | 3.79 | Effectiveness and safety of indomethacin versus ibuprofen for the treatment of patent ductus arteriosus in preterm infants. ( Bali, V; Harabor, A; Kamaluddeen, M; Sivanandan, S; Soraisham, AS, 2013) |
"Postnatal indomethacin is reportedly associated with an increased incidence of necrotizing enterocolitis (NEC) in preterm infants." | 3.77 | The risk of necrotizing enterocolitis after indomethacin tocolysis. ( Holzhausen, KA; Kellogg, H; Lulic-Botica, M; Pruder, S; Salari, V; Sood, BG; Thomas, R, 2011) |
" neonatologists reported that they would ligate a PDA when infants with birth weights <900 g required mechanical ventilation (and indomethacin was contraindicated or had failed to close the PDA), U." | 3.76 | Feeding practices and patent ductus arteriosus ligation preferences-are they related? ( Clyman, RI; Jhaveri, N; Soll, RF, 2010) |
"There were no statistically significant differences between the two protocol groups when comparing percentages of neonates with gestational age≤28 weeks, birth weight≤1000 g, male gender or receiving indomethacin for the indication of PDA prophylaxis vs." | 3.76 | Comparison of two neonatal indomethacin protocols: efficacy and outcome for patent ductus arteriosus closure. ( Chorne, N; Rosito, G; Sum, K, 2010) |
"Our objective was to determine the effect of chorioamnionitis on plasma prostaglandin E2 (PGE2) and thromboxane B2 (TxB2) during the first week in preterm infants." | 3.74 | Chorioamnionitis and ontogeny of circulating prostaglandin and thromboxane in preterm infants. ( Aranda, JV; Glibetic, M; Natarajan, G; Thomas, RL, 2008) |
"Diet, indomethacin, and early use of dexamethasone have been implicated as possible causes of necrotizing enterocolitis and intestinal perforation." | 3.74 | Prevention of necrotizing enterocolitis in preterm infants: a 20-year experience. ( Achanti, B; Lilien, L; Mehta, SK; Pietz, J; Stepka, EC, 2007) |
"Dexamethasone or indomethacin predisposes very low birth weight (VLBW) neonates to spontaneous intestinal perforation (SIP)." | 3.73 | Concurrent use of indomethacin and dexamethasone increases the risk of spontaneous intestinal perforation in very low birth weight neonates. ( Friedlich, P; Paquette, L; Ramanathan, R; Seri, I, 2006) |
"Preterm infants with exposure to antenatal indomethacin might be at increased risk of grade I and II intraventricular haemorrhage and those with both ante- and postnatal exposure at an increased risk of necrotising enterocolitis and sepsis." | 3.70 | Perinatal indomethacin treatment and neonatal complications in preterm infants. ( Ikonen, S; Ojala, R; Tammela, O, 2000) |
"Sequential bleeding times were performed on 25 preterm infants receiving intravenous indomethacin for closure of the patent ductus arteriosus." | 3.67 | Prolonged bleeding time in preterm infants receiving indomethacin for patent ductus arteriosus. ( Bejar, R; Corazza, MS; Cvetnic, W; Davis, RF; Merritt, TA, 1984) |
"This is a case report of focal intestinal perforation in a premature neonate following intravenous administration of indomethacin for patent ductus arteriosus." | 3.67 | Localized intestinal perforation following intravenous indomethacin in premature infants. ( Leonard, AS; Snover, DC; Wolf, WM, 1989) |
"Within 9 months we observed intestinal perforations in three very low birth weight (VLBW) infants undergoing indomethacin treatment for symptomatic patent ductus arteriosus (sPDA)." | 3.67 | Intestinal perforation associated with indomethacin treatment in premature infants. ( Bolkenius, M; Kühl, G; Seyberth, HW; Wille, L, 1985) |
" Intravenous indomethacin was administered to 67 infants with successful closure in 91% of the patients and in 83% of those with birth weights less than 1,000 g." | 3.66 | Parenteral indomethacin for closure of the patent ductus arteriosus. Clinical experience with 67 preterm infants. ( Alexson, CG; Harris, JP; Longfield, L; Manning, JA; Merritt, TA, 1982) |
" Four had severe hyaline membrane disease and one had chronic bronchopulmonary dysplasia; all received furosemide." | 3.66 | Urinary excretion of prostaglandin E following the administration of furosemide and indomethacin to sick low-birth-weight infants. ( Demers, LM; Friedman, Z; Maisels, MJ; Marks, KH; Uhrmann, S, 1978) |
"Failure of closure of the patent ductus arteriosus (PDA) may be associated with harm." | 2.79 | A randomised placebo-controlled trial of early treatment of the patent ductus arteriosus. ( Evans, N; Gill, A; Jeffery, M; Kluckow, M, 2014) |
"A significant patent ductus arteriosus (PDA) is a common finding in the first days of life and, if persistent, is associated with an increased morbidity and mortality in the preterm newborn." | 2.75 | Effect of indomethacin infused over 30 minutes on cerebral fractional tissue oxygen extraction in preterm newborns with a patent ductus arteriosus. ( Bos, AF; Keating, P; ter Horst, H; van Hoften, J; Verhagen, E, 2010) |
"Indomethacin dosing was withheld in the BNP-guided group if the 12 or 24 h BNP concentrations were found to be <100 pg/ml." | 2.74 | B-type natriuretic peptide concentrations to guide treatment of patent ductus arteriosus. ( Attridge, JT; Kaufman, DA; Lim, DS, 2009) |
"Ibuprofen has the same efficiency as indomethacin for the treatment of symptomatic patent ductus arteriosus in preterm infants and less likely to induce necrotizing enterocolitis and renal toxicity than indomethacin." | 2.71 | A comparison of oral ibuprofen and intravenous indomethacin for closure of patent ductus arteriosus in preterm infants. ( Chotigeat, U; Jirapapa, K; Layangkool, T, 2003) |
"Ibuprofen has recently been shown to be effective in closing PDA with fewer hemodynamic effects." | 2.71 | [Ibuprofen versus indomethacin in the treatment of patent ductus arteriosus in preterm infants]. ( Cano Sánchez, A; Carrasco Moreno, JI; Fernández Gilino, C; Gimeno Navarro, A; Gutiérrez Laso, A; Izquierdo Macián, I; Morcillo Sopena, F, 2005) |
"To evaluate whether a prolonged low-dose course of indomethacin would produce an improved closure rate and have fewer side effects compared with a short standard dosage schedule in the management of patent ductus arteriosus (PDA) in preterm infants." | 2.69 | Short versus prolonged indomethacin therapy for patent ductus arteriosus in preterm infants. ( Iivainen, T; Ikonen, S; Janas, M; Koivisto, M; Lautamatti, V; Ojala, R; Pokela, ML; Tammela, O, 1999) |
" One group received 3 doses of intravenous indomethacin at the dosage of 0." | 2.69 | Indomethacin prophylaxis for patent ductus arteriosus (PDA) in infants with a birth weight of less than 1250 grams. ( Khowsathit, P; Patchakapati, B; Supapannachart, S, 1999) |
"Tocolysis in advanced preterm labor delays delivery by more than 48 hours in 50% of patients." | 2.68 | Tocolysis in advanced preterm labor: impact on neonatal outcome. ( Barke, JI; de Veciana, M; Major, CA; Porto, M, 1995) |
"Fourteen preterm infants with patent ductus arteriosus were studied during three subsequent indomethacin bolus administrations with intervals of 12 and 24 h." | 2.67 | Effects of repeated indomethacin administration on cerebral oxygenation and haemodynamics in preterm infants: combined near infrared spectrophotometry and Doppler ultrasound study. ( Hopman, JC; Kollée, LA; Liem, KD; Oeseburg, B, 1994) |
"Four indomethacin-treated and three saline solution-treated infants had parenchymal extension of the hemorrhage." | 2.67 | Low-dose indomethacin therapy and extension of intraventricular hemorrhage: a multicenter randomized trial. ( Allan, W; Ehrenkranz, RA; Katz, KH; Makuch, RW; Ment, LR; Oh, W; Phillip, AG; Schneider, KC; Taylor, KJ; Vohr, B, 1994) |
"This study examined the response of the patent ductus arteriosus (PDA) to intravenous Indomethacin using serial two dimensional and Doppler echocardiography and documented the complications associated with therapy." | 2.67 | Intravenous indomethacin therapy in preterm neonates with patent ductus arteriosus. ( Rajadurai, VS; Yu, VY, 1991) |
"Over a 4-year period, 63 premature babies presenting with patent ductus arteriosus were treated with indomethacin at two different dosage levels (0." | 2.66 | [Treatment of patent ductus arteriosus in premature infants by indomethacin]. ( Bianchetti, G; Marchal, F; Monin, P; Morselli, P; Vert, P, 1987) |
"Treatment with indomethacin prolonged bleeding time, raised serum creatinine concentrations, and was associated with gastrointestinal haemorrhage in seven infants." | 2.66 | Early administration of indomethacin to preterm infants. ( Cooke, RW; Doyle, J; Rennie, JM, 1986) |
"The indomethacin-treated group had significant decreases in serum prostaglandin values 30 hours after the initiation of therapy." | 2.66 | Randomized indomethacin trial for prevention of intraventricular hemorrhage in very low birth weight infants. ( Duncan, CC; Ehrenkranz, RA; Gettner, P; Kleinman, CS; Ment, LR; Pitt, BR; Scott, DT; Stewart, WB; Taylor, KJ, 1985) |
"The 75% patent ductus arteriosus closure rate with indomethacin treatment in phase 1 was not statistically significant due to a 44% spontaneous closure rate in the control group." | 2.65 | Indomethacin treatment for symptomatic patent ductus arteriosus: a double-blind control study. ( Aziz, KU; Hunt, CE; Newfeld, EA; Wilson, A; Yanagi, RM, 1981) |
"The pathophysiology leading to preterm labor is not well understood and often multifactorial; initiating factors include intrauterine infection, inflammation, ischemia, overdistension, and hemorrhage." | 2.48 | Tocolytic therapy for acute preterm labor. ( Abramovici, A; Cantu, J; Jenkins, SM, 2012) |
"Although ongoing patency of the ductus arteriosus is common in small extremely preterm infants, consensus is lacking regarding its clinical significance and treatment strategies." | 2.48 | The ductus arteriosus: a refined approach! ( McNamara, PJ; Sehgal, A, 2012) |
"Although a moderate-sized patent ductus arteriosus (PDA) needs to be closed by the time a child is 1-2 years old, there is great uncertainty about whether it needs to be closed during the neonatal period." | 2.48 | Patent ductus arteriosus: are current neonatal treatment options better or worse than no treatment at all? ( Clyman, RI; Couto, J; Murphy, GM, 2012) |
""Patent ductus arteriosus is one of most common problems that physicians caring for preterm infants have to face." | 2.47 | Patent ductus arteriosus: wait and see? ( Ciarmoli, E; Mosca, F; Schena, F, 2011) |
"Persistent patent ductus arteriosus (PDA) is associated with mortality and morbidity in preterm infants." | 2.46 | Prophylactic intravenous indomethacin for preventing mortality and morbidity in preterm infants. ( Davis, PG; Fowlie, PW; McGuire, W, 2010) |
"Indomethacin has long been the drug of choice." | 2.45 | Therapeutic closure of the ductus arteriosus: benefits and limitations. ( Boubred, F; Mercanti, I; Simeoni, U, 2009) |
"Indomethacin is a prostaglandin inhibitor used to treat patent ductus arteriosus (PDA) in preterm infants." | 2.44 | Prolonged versus short course of indomethacin for the treatment of patent ductus arteriosus in preterm infants. ( Davis, P; Herrera, C; Holberton, J, 2007) |
" The drug has prolonged elimination (plasma half-life = ca 23 hours), suggesting that once daily dosing is appropriate." | 2.43 | Systematic review: intravenous Ibuprofen in preterm newborns. ( Aranda, JV; Thomas, R, 2006) |
"Indomethacin is a prostaglandin inhibitor used to treat patent ductus arteriosus (PDA) in preterm infants." | 2.42 | Prolonged versus short course of indomethacin for the treatment of patent ductus arteriosus in preterm infants. ( Davis, P; Herrera, C; Holberton, J, 2004) |
"Indomethacin has been used successfully to treat symptomatic PDA and may also prevent or limit IVH in the neonatal period." | 2.41 | Prophylactic intravenous indomethacin for preventing mortality and morbidity in preterm infants. ( Davis, PG; Fowlie, PW, 2002) |
"Indomethacin is used to treat symptomatic patent ductus arteriosus and may prevent or limit intraventricular haemorrhage in the neonatal period." | 2.41 | Intravenous indomethacin for preventing mortality and morbidity in very low birth weight infants. ( Fowlie, PW, 2000) |
"Indomethacin was used for median (IQR) 3 (2-5) days while ibuprofen was given for 3 (2-4) days, at a median of 8 and 10 days after birth, respectively; surgical treatment was used later at 33 (24-45) days after birth." | 1.72 | Management of patent ductus arteriosus in very preterm infants in England and Wales: a retrospective cohort study. ( Al-Turkait, A; Choonara, I; Ojha, S; Szatkowski, L, 2022) |
"Few studies exist that have evaluated the effects of indomethacin dosing frequency as a factor associated with successful patent ductus arteriosus closure in very low birth weight neonates." | 1.51 | Indomethacin dosing strategy and neonatal patent ductus arteriosus closure. ( Messina, C; Mintzer, JP; Rathi, P, 2019) |
"Indomethacin has vasoactive properties in cerebral and systemic vascular beds, and it improves cerebral autoregulatory ability." | 1.39 | Tocolytic indomethacin: effects on neonatal haemodynamics and cerebral autoregulation in the preterm newborn. ( Baerts, W; Derks, JB; Lemmers, PM; Thewissen, L; van Bel, F, 2013) |
"Indomethacin prophylaxis was given at <6 hours of life in 730 infants and at >6 hours of life to 168 infants." | 1.39 | Indomethacin prophylaxis to prevent intraventricular hemorrhage: association between incidence and timing of drug administration. ( Laptook, A; Mirza, H; Oh, W; Stonestreet, BS; Tucker, R; Vohr, B, 2013) |
"Reports of Bartter syndrome in premature neonates are rare." | 1.39 | Bartter syndrome: presentation in an extremely premature neonate. ( Calhoun, DA; Flores, FX; Ojeda, FJ, 2013) |
"Indomethacin has been also used in women with short cervices as well as in those with idiopathic polyhydramnios." | 1.38 | Indomethacin in pregnancy: applications and safety. ( Abou-Ghannam, G; Nassar, AH; Usta, IM, 2012) |
"Multiple indomethacin courses using the standard dosing approach result in high PDA closure rates for infants < 29 weeks gestation." | 1.38 | Patent ductus arteriosus in infants <29 weeks gestation--outcomes and factors affecting closure. ( Kapoor, V; Popat, H; Travadi, J, 2012) |
"The effect of patent ductus arteriosus (PDA) treatment with cyclooxygenase (COX) inhibitors (indomethacin [INDO] and ibuprofen [IBU]) on regional oxygenation requires further clarification." | 1.38 | Does treatment of patent ductus arteriosus with cyclooxygenase inhibitors affect neonatal regional tissue oxygenation? ( Bhatt, M; Mehta, R; Petrova, A, 2012) |
"In ibuprofen group, there was no correlation of AQP2 level with urinary osmolality." | 1.37 | Urinary aquaporin-2 excretion during ibuprofen or indomethacin treatment in preterm infants with patent ductus arteriosus. ( Aperia, A; Casper, C; Li, Y; Marcoux, MO; Plat-Willson, G; Zelenina, M, 2011) |
"Neonatal Bartter syndrome is a rare condition, usually revealed by alkalosis and hypokalemia." | 1.35 | [Neonatal Bartter syndrome's special features in very premature newborns]. ( André, JL; Feldmann, M; Hamon, I; Hascoët, JM; Vieux, R, 2009) |
"Optimal time to surgical ligation of patent ductus arteriosus (PDA) in very-low-birth-weight (< 1500 g) premature infants remains an area of controversy." | 1.35 | Early or late surgical ligation of medical refractory patent ductus arteriosus in premature infants. ( Chang, WC; Hsiao, CC; Tsao, LY; Wung, JT, 2009) |
"The use of indomethacin to treat patent ductus arteriosus in preterm infants may either decrease the incidence of necrotizing enterocolitis by stabilizing or closing the ductus arteriosus or increase its incidence by a direct constricting effect on mesenteric blood vessels." | 1.33 | Patent ductus arteriosus, indomethacin and necrotizing enterocolitis in very low birth weight infants: a population-based study. ( Dollberg, S; Lusky, A; Reichman, B, 2005) |
"Surgical ligation of patent ductus arteriosus (PDA) is widely practised in preterm infants despite no clear evidence that this improves outcomes." | 1.33 | Is surgical ligation of patent ductus arteriosus necessary? The Western Australian experience of conservative management. ( Brooks, JM; Doherty, DA; Patole, SK; Simmer, K; Travadi, JN, 2005) |
"Ibuprofen treatment caused a significant decrease in urinary AVP (UAVP/Ucr 24." | 1.33 | Urinary ET-1, AVP and sodium in premature infants treated with indomethacin and ibuprofen for patent ductus arteriosus. ( Faggian, D; Favaro, F; Lago, P; Plebani, M; Trevisanuto, D; Vedovato, S; Zanardo, V, 2005) |
"Indomethacin use has been implicated as a co-risk factor for SIP when combined with glucocorticoids, but previous evidence argued against indomethacin being an independent risk factor when used prophylactically." | 1.33 | New insights into spontaneous intestinal perforation using a national data set: (1) SIP is associated with early indomethacin exposure. ( Attridge, JT; Clark, R; Gordon, PV; Walker, MW, 2006) |
"Symptomatic patent ductus arteriosus (sPDA) is a common problem in premature infants and can be treated effectively with intravenous indomethacin, leading to permanent ductal closure in 70% to 80% of infants." | 1.33 | Effectiveness and side effects of an escalating, stepwise approach to indomethacin treatment for symptomatic patent ductus arteriosus in premature infants below 33 weeks of gestation. ( Beedgen, B; Brüssau, J; Feneberg, R; Huppertz, C; Linderkamp, O; Pöschl, J; Sperandio, M, 2005) |
"The patent ductus arteriosus was confirmed by echocardiography." | 1.31 | [Dopplersonographic findings in neonates with significant persistent ductus arteriosus]. ( Knüpfer, M; Pulzer, F; Robel-Tillig, E; Vogtmann, C, 2002) |
"Persistent patent ductus arteriosus was more common in those infants delivered within 48 hours of maternal indomethacin exposure (40% versus 20% (p<0." | 1.30 | Antenatal indomethacin--adverse fetal effects confirmed. ( Baxendale, H; Harding, J; McCowan, L; McLeay, E; O'Donnell, C; Souter, D, 1998) |
"Indomethacin treatment was successful in 27 infants." | 1.30 | Surgical ligation of patent ductus arteriosus in very low birth weight infants: is it safe? ( Atkinson, JB; Bustorff-Silva, JM; Fonkalsrud, EW; Perez, CA; Villasenor, E, 1998) |
"Indomethacin tocolysis has been reported to increase the incidence of persistent PDA in premature infants." | 1.30 | Indomethacin tocolysis increases postnatal patent ductus arteriosus severity. ( Eidelman, AI; Ferber, B; Glaser, J; Hammerman, C; Kaplan, M; Schimmel, MS, 1998) |
"9 percent, P = 0." | 1.29 | Neonatal complications after the administration of indomethacin for preterm labor. ( Clyman, RI; Cooper, BA; Kuller, JA; Merrill, J; Norton, ME, 1993) |
"Indomethacin was directly associated with intestinal perforation in 3 patients, and acute renal failure in 1; all 4 died." | 1.29 | Optimal management of patent ductus arteriosus in the neonate weighing less than 800 g. ( Langer, JC; Lau, GY; Pipe, S; Shah, J; Trus, T; Winthrop, AL, 1993) |
"The indomethacin was prepared by diluting the content of the commercially available 25-mg indomethacin capsule with lactose by the method of trituration." | 1.28 | Preterm infants with patent ductus arteriosus: treatment with an enteral preparation of indomethacin. ( Fok, TF; Ho, JK; So, LY; Sung, RY, 1992) |
"In 18 infants the patent ductus arteriosus closed after one course of indomethacin; atrial natriuretic peptide levels decreased from median 1240 pg/ml (range 201-5483 pg/ml) to 266 pg/ml (range 62-1108 pg/ml)." | 1.28 | Atrial natriuretic peptide in the diagnosis of patent ductus arteriosus. ( Carter, N; Hamilton, PA; Littleton, P; Smith, A; Weir, FJ, 1992) |
"Indomethacin infusion was associated with a significant reduction in time averaged mean velocity (TAMV), peak systolic velocity (PSV), and end diastolic velocity in both the anterior cerebral artery and middle cerebral artery." | 1.28 | Regional cerebral blood flow velocity changes after indomethacin infusion in preterm infants. ( Austin, NC; Hall, MA; Hames, TK; Pairaudeau, PW, 1992) |
" We recommend the use of MA for closure of symptomatic PDA in preterms, especially in those cases where indomethacin is not tolerated or when minute titration of its dosage is impracticable." | 1.28 | Therapy of symptomatic patent ductus arteriosus in preterms using mefenemic acid and indomethacin. ( Merchant, RH; Sakhalkar, VS, 1992) |
"Indomethacin was given as part of tocolytic management to mothers with a high incidence of early rupture of membranes and preterm labour; and 76 fetuses were exposed to the drug as a result." | 1.28 | Cerebral lesions in preterm infants after tocolytic indomethacin. ( Baerts, W; Fetter, WP; Hop, WC; Sauer, PJ; Spritzer, R; Wallenburg, HC, 1990) |
"We present pharmacokinetic data of prolonged, intra-arterial indomethacin treatment (i." | 1.28 | Pharmacokinetics of intra-arterial indomethacin treatment for patent ductus arteriosus. ( Pollak, A; Salzer, HR; Salzer-Muhar, U; Vergesslich, KA; Weninger, M, 1989) |
"The incidence and evolution of patent ductus arteriosus (PDA) was evaluated in twins and preterm singletons with birth weight less than or equal to 1750 g admitted to our Department in 1987 for respiratory distress syndrome (RDS)." | 1.28 | Does the respiratory distress syndrome in twins and singletons run different risks of persistent ductus arteriosus? ( Foti, P; Milanesi, O; Stellin, G; Trevisanuto, D; Zambon, P; Zanardo, V, 1989) |
"A haemodynamically significant, patent ductus arteriosus in mechanically ventilated preterm infants can be closed by two means today, either medical or surgical." | 1.28 | [Indomethacin or ligation in the treatment of persistent ductus arteriosus: a report of clinical experiences]. ( Fürnkranz, H; Sterniste, W, 1989) |
"A case of early onset Bartter's syndrome associated with hydramnios, prematurity, hypercalciuria and nephrocalcinosis is reported." | 1.27 | A variant of Bartter's syndrome. Bartter's syndrome associated with hydramnios, prematurity, hypercalciuria and nephrocalcinosis. ( Akhtar, M; Cumming, W; Ohlsson, A; Serenius, F; Sieck, U, 1984) |
"The necessity of an early closure of a patent ductus arteriosus is now admitted in the very premature infant, but the use of indomethacin in the first days of life is often impossible because of its side-effects." | 1.27 | [Surgical ligation of patent ductus arteriosus in the very-low-birth-weight premature infant]. ( Couturier, C; Estève, C; Laguenie, G; Murat, I; Saint-Maurice, JP, 1983) |
"Infants who experienced a recurrence of symptomatic PDA had lower birth weights and had received indomethacin at an earlier postnatal age than did infants with a sustained effect." | 1.27 | Recurrence of symptomatic patent ductus arteriosus in extremely premature infants, treated with indomethacin. ( Cotton, RB; Graham, TP; Leheup, B; Lindstrom, DP; Mellander, M; Palme, C; Stahlman, MT, 1984) |
" The margin between closure of the ductus arteriosus and the deterioration of kidney function in preterm infants treated with a presently recommended indomethacin dosage is too narrow." | 1.27 | [Therapeutic problems with indomethacin in preterm infants with persistent ductus arteriosus]. ( Müller, H; Plückthun, H; Seyberth, HW; Ulmer, HE; Wille, L; Wolf, D, 1983) |
"Appropriate management of preterm labor mandates early recognition of subtle signs and symptoms; successful therapy is dependent on this issue." | 1.27 | Preterm labor: its diagnosis and management. ( Creasy, RK; Gonik, B, 1986) |
"Indomethacin treatment for 1 week monitored by drug level determinations was evaluated in 32 preterm infants with symptomatic patent ductus arteriosus (sPDA)." | 1.27 | Prolonged indomethacin treatment in preterm infants with symptomatic patent ductus arteriosus: efficacy, drug level monitoring, and patient selection. ( Isken, V; Kühl, PG; Leonhardt, A; Seyberth, HW, 1987) |
" Patients with this renal disorder require a permanent high dosed indomethacin therapy." | 1.27 | [The significance of renal prostaglandins for kidney function in early childhood]. ( Seyberth, HW, 1987) |
"Indomethacin was infused intravenously in five infants." | 1.27 | The effect of indomethacin on cerebral blood-flow velocity in premature infants. ( Archer, LN; Evans, DH; Levene, MI, 1987) |
"Issues of the pharmacologic therapy of preterm labor, enhancement of lung maturity, and management of labor and delivery are discussed." | 1.27 | Obstetric management of the very low birth weight fetus. ( Hayashi, RH; Marshall, CL, 1986) |
" Qualitative and quantitative differences in pharmacokinetics and pharmacodynamics of drugs should be considered before dosage regimens can be established." | 1.27 | [Peculiarities of drug therapy in childhood]. ( Kusenbach, G; Reinhardt, D, 1986) |
"Indomethacin was given by suppository to 18 neonates for the treatment of patent ductus arteriosus." | 1.27 | Indomethacin therapy of patent ductus in preterm infants controlled by plasma levels. ( Harvey, DP; Lewis, IG; Maxwell, GM, 1985) |
" The mean half-life of elimination (20." | 1.26 | Pharmacokinetics of intravenously administered indomethacin in premature infants. ( Carr, I; Luken, JA; Pildes, RS; Raval, D; Thalji, AA; Yeh, TF, 1980) |
"Indomethacin was administered from the 20th to the 34th week of gestation to 51 women (59 fetuses) in whom bed rest and a beta-mimetic compound (ritodrine) had failed to stop preterm labor." | 1.26 | Perinatal hazards of chronic antenatal tocolysis with indomethacin. ( Baele, G; Derom, R; Thiery, M; Van Egmond, H; Van Kets, H, 1979) |
"Indomethacin constricts the patent ductus arteriosus in approximately 70% of premature infants, but temporarily inhibits synthesis of all prostaglandins." | 1.26 | Operation or indomethacin for the premature ductus. ( Edmunds, LH, 1978) |
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 122 (38.13) | 18.7374 |
1990's | 54 (16.88) | 18.2507 |
2000's | 83 (25.94) | 29.6817 |
2010's | 57 (17.81) | 24.3611 |
2020's | 4 (1.25) | 2.80 |
Authors | Studies |
---|---|
Miller, CJ | 1 |
Prusakov, P | 1 |
Magers, J | 1 |
Speaks, S | 1 |
Sacic, H | 1 |
Escobar, K | 1 |
Abdel-Rasoul, M | 1 |
Nelin, LD | 1 |
Cambonie, G | 1 |
Rozé, JC | 1 |
Marchand-Martin, L | 1 |
Marret, S | 1 |
Durrmeyer, X | 1 |
Torchin, H | 1 |
Ancel, PY | 1 |
Al-Turkait, A | 1 |
Szatkowski, L | 1 |
Choonara, I | 1 |
Ojha, S | 1 |
Yao, SL | 1 |
Smit, E | 1 |
Odd, D | 1 |
Rathi, P | 1 |
Messina, C | 1 |
Mintzer, JP | 1 |
Foglia, EE | 1 |
Roberts, RS | 4 |
Stoller, JZ | 1 |
Davis, PG | 4 |
Haslam, R | 1 |
Schmidt, B | 5 |
Lewis, T | 1 |
Van Haandel, L | 1 |
Scott, A | 1 |
Leeder, JS | 1 |
Kaur, S | 1 |
Stritzke, A | 1 |
Soraisham, AS | 2 |
Lei, C | 1 |
Liu, H | 1 |
Wang, H | 1 |
Liu, C | 1 |
Kemmochi, M | 1 |
Senzaki, H | 1 |
Miyaji, K | 1 |
Hashimoto, M | 1 |
Yamaguchi, A | 1 |
Ooka, M | 1 |
Yokozeki, Y | 1 |
Ishii, M | 1 |
Sallmon, H | 1 |
Aydin, T | 1 |
Hort, S | 1 |
Kubinski, A | 1 |
Bode, C | 1 |
Klippstein, T | 1 |
Endesfelder, S | 1 |
Bührer, C | 1 |
Koehne, P | 1 |
Chiba, H | 1 |
Masutani, S | 1 |
Toyoshima, K | 1 |
Mori, R | 1 |
Baerts, W | 2 |
van Bel, F | 1 |
Thewissen, L | 1 |
Derks, JB | 1 |
Lemmers, PM | 1 |
Mirza, H | 1 |
Oh, W | 7 |
Laptook, A | 2 |
Vohr, B | 6 |
Tucker, R | 2 |
Stonestreet, BS | 2 |
Flores, FX | 1 |
Ojeda, FJ | 1 |
Calhoun, DA | 1 |
Saida, K | 1 |
Nakamura, T | 1 |
Hiroma, T | 1 |
Takigiku, K | 1 |
Yasukochi, S | 1 |
Kluckow, M | 2 |
Jeffery, M | 1 |
Gill, A | 1 |
Evans, N | 3 |
Nagasawa, H | 1 |
Terazawa, D | 1 |
Kohno, Y | 1 |
Yamamoto, Y | 1 |
Kondo, M | 1 |
Sugawara, M | 1 |
Koyama, T | 1 |
Miura, R | 1 |
Coceani, F | 3 |
ElHassan, NO | 1 |
Bird, TM | 1 |
King, AJ | 1 |
Ambadwar, PB | 1 |
Jaquiss, RD | 1 |
Kaiser, JR | 1 |
Robbins, JM | 1 |
Chhina, AS | 1 |
Sharma, BK | 1 |
Raja, M | 1 |
Singhal, M | 1 |
Shenoi, A | 1 |
Tu, YF | 1 |
Wang, LW | 1 |
Wang, ST | 1 |
Yeh, TF | 11 |
Huang, CC | 1 |
Vettukattil, JJ | 1 |
Samuel, BP | 1 |
Stuive, AJ | 1 |
Eding, DM | 1 |
Haw, MP | 1 |
Talavera, MM | 1 |
Bixler, G | 1 |
Cozzi, C | 1 |
Dail, J | 1 |
Miller, RR | 1 |
McClead, R | 1 |
Reber, K | 1 |
Kalani, M | 1 |
Shariat, M | 1 |
Khalesi, N | 1 |
Farahani, Z | 1 |
Ahmadi, S | 1 |
Zanardo, V | 4 |
Vedovato, S | 2 |
Chiozza, L | 1 |
Faggian, D | 2 |
Favaro, F | 2 |
Trevisanuto, D | 4 |
Giardini, A | 1 |
Derrick, G | 1 |
Natarajan, G | 1 |
Glibetic, M | 1 |
Thomas, RL | 1 |
Aranda, JV | 4 |
Busalt, M | 1 |
Attridge, JT | 3 |
Kaufman, DA | 1 |
Lim, DS | 1 |
Vieux, R | 1 |
Hamon, I | 1 |
Feldmann, M | 1 |
André, JL | 1 |
Hascoët, JM | 1 |
Gordon, PV | 2 |
Golombek, SG | 1 |
Sola, A | 1 |
Baquero, H | 1 |
Borbonet, D | 1 |
Cabañas, F | 1 |
Fajardo, C | 1 |
Goldsmit, G | 1 |
Lemus, L | 1 |
Miura, E | 1 |
Pellicer, A | 1 |
Pérez, JM | 1 |
Rogido, M | 1 |
Zambosco, G | 1 |
van Overmeire, B | 3 |
Hsiao, CC | 1 |
Wung, JT | 1 |
Tsao, LY | 1 |
Chang, WC | 1 |
Luu, TM | 2 |
Ment, LR | 10 |
Schneider, KC | 6 |
Katz, KH | 7 |
Allan, WC | 4 |
Vohr, BR | 3 |
Carmo, KB | 1 |
Paradisis, M | 1 |
Noori, S | 1 |
Seri, I | 3 |
Mercanti, I | 1 |
Boubred, F | 1 |
Simeoni, U | 2 |
Beharry, KD | 1 |
Valencia, GB | 1 |
Benitz, WE | 1 |
Jhaveri, N | 1 |
Soll, RF | 2 |
Clyman, RI | 14 |
Chen, S | 1 |
Tacy, T | 1 |
Clyman, R | 1 |
Keating, P | 1 |
Verhagen, E | 1 |
van Hoften, J | 1 |
ter Horst, H | 1 |
Bos, AF | 1 |
Katayama, Y | 1 |
Minami, H | 1 |
Enomoto, M | 1 |
Takano, T | 1 |
Hayashi, S | 1 |
Lee, YK | 1 |
Sehgal, A | 2 |
Bajaj, R | 1 |
Narasimhan, R | 1 |
Fowlie, PW | 5 |
McGuire, W | 2 |
Rosito, G | 1 |
Sum, K | 1 |
Chorne, N | 1 |
Jones, LJ | 1 |
Craven, PD | 1 |
Attia, J | 1 |
Thakkinstian, A | 1 |
Wright, I | 1 |
Li, Y | 1 |
Zelenina, M | 1 |
Plat-Willson, G | 1 |
Marcoux, MO | 1 |
Aperia, A | 1 |
Casper, C | 1 |
DeMauro, SB | 1 |
Brissaud, O | 1 |
Guichoux, J | 1 |
Sood, BG | 1 |
Lulic-Botica, M | 1 |
Holzhausen, KA | 1 |
Pruder, S | 1 |
Kellogg, H | 1 |
Salari, V | 1 |
Thomas, R | 2 |
Seshia, M | 1 |
Shankaran, S | 2 |
Mildenhall, L | 1 |
Tyson, J | 1 |
Lui, K | 1 |
Fok, T | 1 |
Roberts, R | 1 |
Abou-Ghannam, G | 1 |
Usta, IM | 1 |
Nassar, AH | 1 |
Schena, F | 1 |
Ciarmoli, E | 1 |
Mosca, F | 2 |
Dani, C | 1 |
Fanos, V | 1 |
Pusceddu, M | 1 |
Dessì, A | 1 |
Marcialis, MA | 1 |
Garner, RS | 1 |
Miller, C | 1 |
Burchfield, DJ | 1 |
Adrouche-Amrani, L | 1 |
Green, RS | 1 |
Gluck, KM | 1 |
Lin, J | 1 |
Popat, H | 1 |
Kapoor, V | 1 |
Travadi, J | 1 |
Maruyama, K | 1 |
Fujiu, T | 1 |
Abramovici, A | 1 |
Cantu, J | 1 |
Jenkins, SM | 1 |
McNamara, PJ | 1 |
Hammerman, C | 6 |
Bin-Nun, A | 1 |
Kaplan, M | 3 |
Couto, J | 1 |
Murphy, GM | 1 |
Bhatt, M | 1 |
Petrova, A | 1 |
Mehta, R | 1 |
Wadhawan, R | 1 |
Saha, S | 1 |
Das, A | 1 |
Bell, EF | 1 |
Stoll, BJ | 1 |
Walsh, MC | 1 |
Higgins, R | 1 |
Wickremasinghe, AC | 1 |
Rogers, EE | 1 |
Piecuch, RE | 1 |
Johnson, BC | 1 |
Golden, S | 1 |
Moon-Grady, AJ | 1 |
Davis, JS | 1 |
Ryan, ML | 1 |
Shields, JM | 1 |
Sola, JE | 1 |
Perez, EA | 1 |
Neville, HL | 1 |
Rodriguez, MM | 1 |
Knott, EM | 1 |
Zamora, A | 1 |
Cavett, C | 1 |
Wattsman, TA | 1 |
Zhang, CC | 1 |
Cheng, GQ | 1 |
Sivanandan, S | 1 |
Bali, V | 1 |
Harabor, A | 1 |
Kamaluddeen, M | 1 |
Wright, LL | 1 |
Davis, P | 3 |
Solimano, A | 1 |
Supapannachart, S | 2 |
Limrungsikul, A | 1 |
Khowsathit, P | 2 |
Allan, W | 3 |
Westerveld, M | 4 |
Duncan, CC | 6 |
Makuch, RW | 6 |
Morley, GM | 1 |
Asztalos, EV | 1 |
Robertson, CM | 1 |
Sauve, RS | 1 |
Whitfield, MF | 1 |
Lee, J | 2 |
Rajadurai, VS | 2 |
Tan, KW | 1 |
Wong, KY | 1 |
Wong, EH | 1 |
Leong, JY | 1 |
Keller, RL | 2 |
Itabashi, K | 1 |
Ohno, T | 1 |
Nishida, H | 1 |
Bellander, M | 1 |
Ley, D | 1 |
Polberger, S | 1 |
Hellström-Westas, L | 1 |
Osborn, DA | 1 |
Su, PH | 1 |
Chen, JY | 1 |
Su, CM | 1 |
Huang, TC | 1 |
Lee, HS | 1 |
Shah, S | 1 |
Chotigeat, U | 1 |
Jirapapa, K | 1 |
Layangkool, T | 1 |
Herrera, C | 2 |
Holberton, J | 2 |
Dollberg, S | 1 |
Lusky, A | 1 |
Reichman, B | 1 |
Distefano, G | 1 |
Brooks, JM | 2 |
Travadi, JN | 2 |
Patole, SK | 2 |
Doherty, DA | 2 |
Simmer, K | 1 |
Doyle, NM | 1 |
Gardner, MO | 1 |
Wells, L | 1 |
Qualls, C | 1 |
Papile, LA | 1 |
Lago, P | 1 |
Plebani, M | 2 |
Gimeno Navarro, A | 1 |
Cano Sánchez, A | 1 |
Fernández Gilino, C | 1 |
Carrasco Moreno, JI | 1 |
Izquierdo Macián, I | 1 |
Gutiérrez Laso, A | 1 |
Morcillo Sopena, F | 1 |
Hasan, SU | 1 |
Tacy, TA | 1 |
Fields, S | 1 |
Ofenstein, JP | 1 |
Clark, R | 1 |
Walker, MW | 1 |
Sperandio, M | 1 |
Beedgen, B | 1 |
Feneberg, R | 1 |
Huppertz, C | 1 |
Brüssau, J | 1 |
Pöschl, J | 1 |
Linderkamp, O | 2 |
Jaillard, S | 1 |
Larrue, B | 1 |
Rakza, T | 1 |
Magnenant, E | 1 |
Warembourg, H | 1 |
Storme, L | 1 |
Miller, SP | 1 |
Mayer, EE | 1 |
Glidden, DV | 1 |
Hamrick, SE | 1 |
Barkovich, AJ | 1 |
Manzar, S | 1 |
Paquette, L | 1 |
Friedlich, P | 1 |
Ramanathan, R | 1 |
Kumaran, V | 1 |
Godambe, S | 1 |
Newby, B | 1 |
Shah, V | 1 |
Shah, PS | 1 |
Pietz, J | 1 |
Achanti, B | 2 |
Lilien, L | 3 |
Stepka, EC | 1 |
Mehta, SK | 1 |
Kawase, Y | 1 |
Ishii, T | 1 |
Arai, H | 1 |
Uga, N | 1 |
Cordero, L | 1 |
Nankervis, CA | 1 |
Delooze, D | 1 |
Giannone, PJ | 1 |
Levene, M | 1 |
Cherif, A | 1 |
Jabnoun, S | 1 |
Khrouf, N | 1 |
Su, BH | 1 |
Lin, HC | 1 |
Chiu, HY | 1 |
Hsieh, HY | 1 |
Chen, HH | 1 |
Tsai, YC | 1 |
Amin, SB | 1 |
Sinkin, RA | 1 |
Glantz, JC | 1 |
Sangem, M | 1 |
Asthana, S | 1 |
Amin, S | 1 |
Kimura, R | 1 |
Lee, KS | 1 |
Herrman, K | 1 |
Bose, C | 1 |
Lewis, K | 1 |
Laughon, M | 1 |
Versmold, HT | 1 |
Raval, D | 5 |
Lilien, LD | 2 |
Srinivasan, G | 2 |
Pildes, RS | 10 |
Kääpä, P | 1 |
Lanning, P | 1 |
Koivisto, M | 2 |
Gersony, WM | 3 |
Peckham, GJ | 2 |
Ellison, RC | 3 |
Miettinen, OS | 2 |
Nadas, AS | 4 |
Pyati, S | 1 |
Drummond, WH | 1 |
Bucciarelli, RL | 1 |
Gessner, IH | 1 |
Monset-Couchard, M | 1 |
Dias-Mançano, D | 1 |
Murat, I | 2 |
Relier, JP | 1 |
Wagner, HR | 1 |
Zierler, S | 2 |
Lang, P | 2 |
Purohit, DM | 1 |
Behrendt, D | 1 |
Waldhausen, JA | 1 |
Seyberth, HW | 6 |
Rascher, W | 1 |
Wille, L | 3 |
Hackenthal, E | 1 |
Ulmer, HE | 2 |
Kraybill, EN | 1 |
Ohlsson, A | 1 |
Sieck, U | 1 |
Cumming, W | 1 |
Akhtar, M | 1 |
Serenius, F | 1 |
Tulassay, T | 1 |
Kiszel, J | 1 |
Csömör, S | 1 |
Regazzi, MB | 1 |
Rondanelli, R | 1 |
Vidale, E | 1 |
Chirico, G | 1 |
Rondini, G | 1 |
Chiara, A | 1 |
Piccolo, A | 1 |
Zarfin, Y | 2 |
Koren, G | 2 |
Perlman, M | 3 |
Dooley, KJ | 1 |
Smallhorn, JF | 1 |
Gow, R | 1 |
Olley, PM | 4 |
Freedom, RM | 1 |
Swyer, PR | 3 |
Rowe, RD | 3 |
Atik, E | 1 |
Moromizato, JH | 1 |
Zan, R | 1 |
Ajzenberg, M | 1 |
Esher, R | 1 |
Diniz, EM | 1 |
Souza, AT | 1 |
Martins, CO | 1 |
Bastos, JC | 1 |
Pedersen, S | 1 |
Frost, L | 1 |
Vázquez, C | 1 |
Cabrera, A | 2 |
Pastor, E | 2 |
Valls y Soler, A | 1 |
Petersen, S | 3 |
Christensen, NC | 3 |
Lauridsen, P | 2 |
Pedersen, SA | 2 |
Ryssing, E | 3 |
Laguenie, G | 1 |
Estève, C | 1 |
Couturier, C | 1 |
Saint-Maurice, JP | 1 |
Mellander, M | 1 |
Leheup, B | 1 |
Lindstrom, DP | 1 |
Palme, C | 1 |
Graham, TP | 1 |
Stahlman, MT | 1 |
Cotton, RB | 3 |
Corazza, MS | 1 |
Davis, RF | 1 |
Merritt, TA | 5 |
Bejar, R | 1 |
Cvetnic, W | 1 |
Chiswick, ML | 1 |
Blinova, EI | 1 |
Aleksi-Meskhishvili, VV | 1 |
Verboom, AJ | 1 |
de Leeuw, R | 1 |
Müller, H | 1 |
Plückthun, H | 1 |
Wolf, D | 1 |
Luken, J | 2 |
Thalji, A | 3 |
Carr, I | 3 |
O'Loughlin, JE | 1 |
Yanagi, RM | 1 |
Wilson, A | 1 |
Newfeld, EA | 1 |
Aziz, KU | 1 |
Hunt, CE | 1 |
Hencz, P | 1 |
Kertész, E | 1 |
Beviz, J | 1 |
Szeleczki, T | 1 |
Szekeres, Z | 1 |
Mahony, L | 1 |
Carnero, V | 1 |
Brett, C | 1 |
Heymann, MA | 5 |
Mullett, MD | 2 |
Croghan, TW | 1 |
Myerberg, DZ | 1 |
Krall, JM | 1 |
Neal, WA | 2 |
Burnard, ED | 1 |
Thomas, DB | 1 |
Grattan-Smith, P | 1 |
Wilks, A | 2 |
Singh, J | 1 |
Betkerur, M | 1 |
Goldbarg, HR | 1 |
Henek, T | 1 |
Friedman, CA | 1 |
Parks, BR | 1 |
Rawson, JE | 1 |
Serwer, GA | 1 |
Anderson, PA | 1 |
Harris, JP | 1 |
Alexson, CG | 1 |
Longfield, L | 1 |
Manning, JA | 1 |
Jaso, E | 1 |
Tejedor, JC | 1 |
Quero, J | 1 |
Pérez Rodríguez, J | 1 |
Agustí, B | 1 |
Castro, J | 1 |
García Frías, E | 1 |
Lozano González, CH | 1 |
Holden, AM | 1 |
Hurtado del Río, D | 1 |
Segura, MA | 1 |
Dalens, B | 1 |
Dechelotte, P | 1 |
Gaulme, J | 1 |
Raynaud, EJ | 1 |
Luken, L | 1 |
Møller Jensen, K | 1 |
Nagaraj, HS | 1 |
Sandhu, AS | 1 |
Cook, LN | 1 |
Buchino, JJ | 1 |
Groff, DB | 1 |
Neu, J | 1 |
Ariagno, RL | 1 |
Johnson, JD | 1 |
Pitlick, PT | 2 |
Cohen, RS | 1 |
Beets, CL | 1 |
Sunshine, P | 1 |
Evans, M | 1 |
Bhat, R | 1 |
Vidyasagar, D | 1 |
Patel, M | 1 |
Hastreiter, A | 1 |
Catterton, Z | 1 |
Sellers, B | 1 |
Gray, B | 1 |
Chantepie, A | 1 |
Gold, F | 1 |
Laugier, J | 1 |
Alpert, BS | 2 |
Lewins, MJ | 2 |
Rowland, DW | 2 |
Grant, MJ | 2 |
Soldin, SJ | 3 |
Gray, PH | 1 |
Pemberton, PJ | 1 |
Vert, P | 2 |
Bianchetti, G | 2 |
Marchal, F | 2 |
Monin, P | 2 |
Morselli, PL | 1 |
Obeyesekere, HI | 1 |
Pankhurst, S | 1 |
Yu, VY | 4 |
Procianoy, RS | 1 |
Garcia-Prats, JA | 2 |
Hittner, HM | 1 |
Adams, JM | 1 |
Rudolph, AJ | 1 |
Yaffe, SJ | 1 |
Friedman, WF | 6 |
Rogers, D | 1 |
Ragni, M | 1 |
Saccar, C | 1 |
Thalji, AA | 1 |
Luken, JA | 1 |
de Veciana, M | 1 |
Porto, M | 1 |
Major, CA | 2 |
Barke, JI | 1 |
Patel, J | 1 |
Marks, KA | 1 |
Roberts, I | 1 |
Azzopardi, D | 1 |
Edwards, AD | 2 |
Glaser, J | 2 |
Schimmel, MS | 2 |
Ferber, B | 2 |
Eidelman, AI | 2 |
Ehrenkranz, RA | 5 |
Philip, AG | 2 |
Liem, KD | 2 |
Hopman, JC | 1 |
Kollée, LA | 1 |
Oeseburg, B | 1 |
Barrington, KJ | 1 |
Fox, M | 1 |
Merrill, JD | 1 |
Norton, ME | 2 |
Hebel, A | 1 |
Grasser, S | 1 |
Phillip, AG | 1 |
Taylor, KJ | 3 |
Merrill, J | 1 |
Cooper, BA | 1 |
Kuller, JA | 1 |
Archer, N | 3 |
Gal, P | 2 |
Gilman, JT | 1 |
Schneider, K | 1 |
Lewis, DF | 1 |
Harding, JA | 1 |
Porto, MA | 1 |
Garite, TJ | 1 |
Trus, T | 1 |
Winthrop, AL | 1 |
Pipe, S | 1 |
Shah, J | 1 |
Langer, JC | 1 |
Lau, GY | 1 |
Zangen, D | 1 |
Buderus, S | 1 |
Thomas, B | 1 |
Fahnenstich, H | 1 |
Kowalewski, S | 1 |
Renfro, WH | 1 |
Burr, JM | 1 |
Rawlings, J | 1 |
Couser, RJ | 1 |
Ferrara, TB | 1 |
Wright, GB | 1 |
Cabalka, AK | 1 |
Schilling, CG | 1 |
Hoekstra, RE | 1 |
Payne, NR | 1 |
Kirsten, D | 1 |
Grosfeld, JL | 1 |
Chaet, M | 1 |
Molinari, F | 1 |
Engle, W | 1 |
Engum, SA | 1 |
West, KW | 1 |
Rescorla, FJ | 1 |
Scherer, LR | 1 |
Scott, DT | 2 |
Bada, HS | 1 |
Bray, M | 1 |
Lattanzio, M | 1 |
Fumagalli, M | 1 |
Tosetto, C | 1 |
Yanowitz, TD | 1 |
Yao, AC | 1 |
Werner, JC | 1 |
Pettigrew, KD | 1 |
Souter, D | 1 |
Harding, J | 1 |
McCowan, L | 1 |
O'Donnell, C | 1 |
McLeay, E | 1 |
Baxendale, H | 1 |
Makuch, R | 1 |
Perez, CA | 1 |
Bustorff-Silva, JM | 1 |
Villasenor, E | 1 |
Fonkalsrud, EW | 1 |
Atkinson, JB | 1 |
Andruscavage, L | 1 |
Shorter, NA | 1 |
Liu, JY | 1 |
Mooney, DP | 1 |
Harmon, BJ | 1 |
Patole, S | 2 |
Whitehall, J | 2 |
Tammela, O | 3 |
Ojala, R | 3 |
Iivainen, T | 1 |
Lautamatti, V | 1 |
Pokela, ML | 1 |
Janas, M | 1 |
Ikonen, S | 2 |
Narayanan, M | 2 |
Schlueter, M | 1 |
Kang, NS | 1 |
Yoo, KH | 1 |
Cheon, H | 1 |
Choi, BM | 1 |
Hong, YS | 1 |
Lee, JW | 1 |
Kim, SK | 1 |
Vermillion, ST | 1 |
Newman, RB | 1 |
Watterberg, KL | 1 |
Scott, SM | 1 |
Backstrom, C | 1 |
Gifford, KL | 1 |
Cook, KL | 1 |
Sparrow, SS | 1 |
Cooper, B | 2 |
Weiss, H | 1 |
Patchakapati, B | 1 |
Zaninotto, M | 1 |
Lachin, M | 1 |
Altinier, S | 1 |
Ferrarese, P | 1 |
Brion, LP | 2 |
Campbell, DE | 2 |
Smets, K | 1 |
Lecoutere, D | 1 |
Van de Broek, H | 2 |
Weyler, J | 2 |
Degroote, K | 1 |
Langhendries, JP | 1 |
Van Laer, P | 1 |
Vanhaesebrouck, P | 2 |
Edstedt-Bonamy, AK | 1 |
Johansson, S | 1 |
Milerad, J | 1 |
Casalaz, D | 1 |
Suzumura, H | 1 |
Nitta, A | 1 |
Tanaka, G | 1 |
Arisaka, O | 1 |
Ruuska, T | 1 |
Karikoski, R | 1 |
Ikonen, RS | 1 |
Bolisetty, S | 1 |
Koh, G | 1 |
Stalewski, H | 1 |
Al-Shawaf, EM | 1 |
Al-Alaiyan, SA | 1 |
Aqeel, AY | 1 |
Gamal, MH | 1 |
Arlettaz, R | 1 |
Wilkinson, AR | 2 |
Robel-Tillig, E | 1 |
Knüpfer, M | 1 |
Pulzer, F | 1 |
Vogtmann, C | 2 |
Christmann, V | 1 |
Semmekrot, BA | 1 |
van de Bor, M | 1 |
Quinn, D | 1 |
Edwards, DK | 1 |
Higgins, CB | 1 |
DiSessa, TG | 1 |
Imre, S | 1 |
Katalin, P | 1 |
Bartel, J | 1 |
Fitzpatrick, KM | 1 |
Feldman, BH | 1 |
Cifuentes, RF | 1 |
Balfe, JW | 1 |
Radde, IC | 1 |
Polgár, M | 1 |
Kemény, J | 1 |
Szirmai, Z | 1 |
Van Kets, H | 1 |
Thiery, M | 2 |
Derom, R | 1 |
Van Egmond, H | 1 |
Baele, G | 1 |
Rudolph, AM | 3 |
Gluck, L | 1 |
Higgins, C | 1 |
Friedman, W | 1 |
Nyhan, WL | 1 |
Friedman, Z | 1 |
Demers, LM | 1 |
Marks, KH | 1 |
Uhrmann, S | 1 |
Maisels, MJ | 1 |
Hoffman, JI | 1 |
Edmunds, LH | 1 |
Hirschklau, MJ | 1 |
Printz, MP | 1 |
Kirkpatrick, SE | 1 |
Silverman, NH | 1 |
So, LY | 1 |
Fok, TF | 1 |
Sung, RY | 1 |
Ho, JK | 1 |
Morales-Suárez, M | 1 |
Lemus-Varela, L | 1 |
Udaeta-Mora, E | 1 |
Cardiel-Marmolejo, L | 1 |
Rodríguez-Balderrama, I | 1 |
Liz-Cedillo, RE | 1 |
Weir, FJ | 1 |
Smith, A | 1 |
Littleton, P | 1 |
Carter, N | 1 |
Hamilton, PA | 1 |
Austin, NC | 1 |
Pairaudeau, PW | 1 |
Hames, TK | 1 |
Hall, MA | 1 |
Sakhalkar, VS | 1 |
Merchant, RH | 1 |
Figueras Aloy, J | 1 |
Vilanova Juanola, JM | 1 |
Molina González, J | 1 |
Jiménez González, R | 1 |
Haywood, JL | 1 |
FitzGerald, GA | 1 |
Satur, CR | 1 |
Walker, DR | 1 |
Dickinson, DF | 1 |
Lamp, KC | 1 |
Reynolds, MS | 1 |
James, C | 1 |
Reed, MD | 1 |
Wyatt, JS | 1 |
Richardson, C | 1 |
Potter, A | 1 |
Cope, M | 1 |
Delpy, DT | 1 |
Reynolds, EO | 1 |
Fetter, WP | 1 |
Hop, WC | 1 |
Wallenburg, HC | 1 |
Spritzer, R | 1 |
Sauer, PJ | 1 |
Steinberg, JD | 1 |
Bambang Oetomo, S | 1 |
Martijn, A | 1 |
Messer, J | 1 |
Weisburd, P | 1 |
Haddad, J | 1 |
Willard, D | 1 |
Weninger, M | 2 |
Pollak, A | 2 |
Salzer-Muhar, U | 2 |
Vergesslich, KA | 1 |
Salzer, HR | 2 |
Volpe, JJ | 2 |
Foti, P | 1 |
Zambon, P | 1 |
Stellin, G | 1 |
Milanesi, O | 1 |
Strasser, T | 1 |
Vogel, M | 1 |
Wolf, WM | 1 |
Snover, DC | 1 |
Leonard, AS | 1 |
Sterniste, W | 1 |
Fürnkranz, H | 1 |
Patel, H | 1 |
Gonik, B | 1 |
Creasy, RK | 1 |
Colditz, P | 1 |
Murphy, D | 1 |
Rolfe, P | 1 |
Morselli, P | 1 |
Leroy, JG | 1 |
Govaert, P | 1 |
de Praeter, C | 1 |
Coppens, M | 1 |
Cuvelier, C | 1 |
Dhont, M | 1 |
Grubbe, G | 1 |
Ruckhäberle, KE | 1 |
Böttcher, H | 1 |
Ockert, C | 1 |
Walters, M | 1 |
Bandstra, ES | 1 |
Montalvo, BM | 1 |
Goldberg, RN | 1 |
Pacheco, I | 1 |
Ferrer, PL | 1 |
Flynn, J | 1 |
Gregorios, JB | 1 |
Bancalari, E | 1 |
Hwang, B | 1 |
Hsieh, KS | 1 |
Tsuei, DH | 1 |
Chen, SJ | 1 |
Meng, CC | 1 |
Perlman, JM | 1 |
Kresch, MJ | 1 |
Moya, FR | 1 |
Ascuitto, RJ | 1 |
Ross-Ascuitto, NT | 1 |
Heusser, F | 1 |
Pryds, O | 1 |
Greisen, G | 1 |
Johansen, KH | 1 |
Kauffman, RE | 1 |
Rennie, JM | 1 |
Doyle, J | 1 |
Cooke, RW | 1 |
Burghard, R | 2 |
Leititis, JU | 2 |
Brandis, M | 2 |
Leonhardt, A | 1 |
Isken, V | 1 |
Kühl, PG | 1 |
Szymonowicz, W | 1 |
Daniel, M | 1 |
Ho, NK | 1 |
Gordjani, N | 1 |
Wildberg, A | 1 |
Valls i Soler, A | 1 |
Benito, J | 1 |
López Heredia, I | 1 |
Santiago, M | 1 |
Evans, DH | 1 |
Levene, MI | 1 |
Archer, LN | 1 |
Marshall, CL | 1 |
Hayashi, RH | 1 |
Ho, LY | 1 |
Silove, ED | 1 |
Reinhardt, D | 1 |
Kusenbach, G | 1 |
Goldberg, SJ | 1 |
Ramsay, JM | 1 |
Murphy, DJ | 1 |
Vick, GW | 1 |
Courtney, JT | 1 |
Huhta, JC | 1 |
Page, GG | 1 |
Kleinman, CS | 1 |
Pitt, BR | 1 |
Stewart, WB | 1 |
Gettner, P | 1 |
Maresky, D | 1 |
MacLeod, S | 1 |
Kühl, G | 1 |
Bolkenius, M | 1 |
Lewis, IG | 1 |
Harvey, DP | 1 |
Maxwell, GM | 1 |
Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
---|---|---|---|---|---|---|---|
Drug Utilization Patterns in Neonatal Units in the UK: a Retrospective Pharmaco-epidemiological Study[NCT03773289] | 642,729 participants (Actual) | Observational | 2018-04-20 | Completed | |||
Dynamic Prediction of Bleeding in Thrombocytopenic Preterm Neonates[NCT06043050] | 1,200 participants (Anticipated) | Observational | 2022-09-26 | Recruiting | |||
Long Term Follow-up of the TREOCAPA (Prophylactic TREatment Of the duCtus Arteriosus in Preterm Infants by Acetaminophen) Study (TREOCAPA-LT)[NCT06064825] | 500 participants (Anticipated) | Observational | 2023-11-30 | Not yet recruiting | |||
The Best Treatment Strategy: Surgical Versus Pharmacological, to Close the Ductus Arteriosus Persistent in Preterm Infants. A Randomized Controlled Trial[NCT02602054] | Phase 2 | 40 participants (Anticipated) | Interventional | 2015-10-31 | Recruiting | ||
Randomized Indomethacin Germinal Matrix Hemorrhage/Intraventricular Hemorrhage (GMH/IVH) Prevention Trial[NCT00033917] | Phase 3 | 630 participants (Actual) | Interventional | 1989-09-30 | Completed | ||
Randomised Controlled Clinical Trial of Echocardiographically Guided Versus Standard Ibuprofen Treatment for Patent Ductus Arteriosus: a Pilot Study[NCT01593163] | Phase 3 | 49 participants (Actual) | Interventional | 2009-05-31 | Completed | ||
Combination of Acetaminophen and Ibuprofen in the Management of Patent Ductus Arteriosus in Premature Infants: A Pilot Study[NCT03103022] | Phase 1 | 20 participants (Actual) | Interventional | 2017-06-12 | Completed | ||
Randomized, Placebo Controlled Trial of Indomethacin for Tocolysis[NCT01869361] | Early Phase 1 | 0 participants (Actual) | Interventional | 2020-08-01 | Withdrawn (stopped due to Due to much lower than expected numbers of eligible patients and lack of PI time, the study was not started.) | ||
Trial of Indomethacin Prophylaxis in Preterm Infants (TIPP)[NCT00009646] | Phase 3 | 1,202 participants (Actual) | Interventional | 1993-11-30 | Completed | ||
Liberal Versus Restrictive Platelet Transfusion for Treatment of Hemodynamically Significant Patent Ductus Arteriosus in Thrombocytopenic Preterm Neonates- A Randomized Open Label, Controlled Trial[NCT03022253] | Phase 3 | 44 participants (Anticipated) | Interventional | 2016-03-31 | Completed | ||
Aspirin Supplementation for Pregnancy Indicated Risk Reduction In Nulliparas (ASPIRIN)[NCT02409680] | 11,976 participants (Actual) | Interventional | 2016-03-23 | Completed | |||
Paracetamol (Acetaminophen) for Closure of PDA in Preterm Infants[NCT01755728] | Phase 3 | 19 participants (Actual) | Interventional | 2013-01-01 | Completed | ||
Lactoferrin Infant Feeding Trial - LIFT_Canada[NCT03367013] | Phase 3 | 453 participants (Actual) | Interventional | 2018-02-16 | Active, not recruiting | ||
Enteral Supplementation With High-dose Docosahexaenoic Acid on the Risk for Bronchopulmonary Dysplasia in Very Preterm Infants: A Collaborative Study Protocol for an Individual Participant Data Meta-analysis[NCT05915806] | 1,801 participants (Actual) | Interventional | 2023-07-30 | Active, not recruiting | |||
Clinical Research on the Predictive Effect of Neonatal Morbidities on the Poor Outcomes to Very Low Birth-weight and Extremely Low Birth-weight Infants[NCT03104946] | 834 participants (Actual) | Observational | 2013-09-01 | Completed | |||
Generic Database: A Survey of Morbidity and Mortality in Very Low Birth Weight Infants[NCT00063063] | 80,000 participants (Anticipated) | Observational | 1987-01-31 | Recruiting | |||
New Therapeutic Approaches to the Resistant Patent Ductus Arteriosus (PDA) in Low Birth Weight Neonates[NCT00616382] | Phase 2 | 68 participants (Anticipated) | Interventional | 2008-03-31 | Not yet recruiting | ||
Intestinal Function in Neonates With Complex Congenital Heart Disease[NCT01475357] | 27 participants (Actual) | Interventional | 2011-10-31 | Completed | |||
Randomized Pilot Study Comparing Oral Ibuprofen With Intravenous Ibuprofen in Very Low Birth Weight Infants With Patent Ductus Arteriosus[NCT00642330] | Phase 4 | 62 participants (Actual) | Interventional | 2007-01-31 | Completed | ||
[NCT00000494] | Phase 3 | 0 participants | Interventional | 1978-09-30 | Completed | ||
Comparison of the Efficacy of IV Acetaminophen Versus IV Indomethacin in Treatment of Hemodynamically Significant PDA in VLBW Infants[NCT03537144] | Phase 3 | 37 participants (Actual) | Interventional | 2016-06-30 | Terminated (stopped due to Difficulty enrolling patients) | ||
Pharmacological Closure of Patent Ductus Arteriosus in Extreme Low Birth Weight Infants. A Comparison of Efficacy, Side Effects and Outcomes Between Indomethacin and Ibuprofen[NCT01758913] | 110 participants (Actual) | Interventional | 2007-02-28 | Completed | |||
[information is prepared from clinicaltrials.gov, extracted Sep-2024] |
Cranial ultrasounds were performed daily for the first 5 postnatal days; the main outcome measure was intraaventricular hemorrhage (IVH) at 5 days of age (NCT00033917)
Timeframe: at 5 days
Intervention | IVH (Number) |
---|---|
Indomethacin | 25 |
Placebo | 40 |
"Peabody Picture Vocabulary Test (PPVT) This is a semantic language test. The mean value is 100; standard deviation is 16 points. A higher score means better language; a lower score means poorer language.~There are no subscales to the PPVT. The measurement unit is points on a scale. A score < 70 indicates severely abnormal language function." (NCT00033917)
Timeframe: at 8 years
Intervention | participants with PPVT score < 70 (Number) |
---|---|
Indomethacin - no IVH | 12 |
Indomethacin - IVH | 5 |
Placebo - no IVH | 24 |
Placebo - IVH | 7 |
- Early preterm delivery (<34 weeks) (NCT02409680)
Timeframe: At delivery
Intervention | Participants (Count of Participants) |
---|---|
Intervention Arm | 189 |
Placebo Arm | 230 |
- Birth weight <2500g (NCT02409680)
Timeframe: At delivery
Intervention | Participants (Count of Participants) |
---|---|
Intervention Arm | 1078 |
Placebo Arm | 1153 |
- Birth weight <1500g (NCT02409680)
Timeframe: At delivery
Intervention | Participants (Count of Participants) |
---|---|
Intervention Arm | 78 |
Placebo Arm | 101 |
- Incidence of Fetal Loss (NCT02409680)
Timeframe: At delivery
Intervention | Participants (Count of Participants) |
---|---|
Intervention Arm | 303 |
Placebo Arm | 353 |
- Incidence of Spontaneous Abortion (NCT02409680)
Timeframe: At delivery
Intervention | Participants (Count of Participants) |
---|---|
Intervention Arm | 134 |
Placebo Arm | 152 |
- Incidence of All stillbirth (NCT02409680)
Timeframe: At delivery
Intervention | Participants (Count of Participants) |
---|---|
Intervention Arm | 141 |
Placebo Arm | 166 |
- Incidence of Medical Termination of Pregnancy (NCT02409680)
Timeframe: At delivery
Intervention | Participants (Count of Participants) |
---|---|
Intervention Arm | 42 |
Placebo Arm | 30 |
- Hypertensive disorders of pregnancy is defined by the characterization of evidence of a hypertensive disorder, including either preeclampsia or eclampsia occurring during the pregnancy. (NCT02409680)
Timeframe: Evidence of hypertensive disorder during the pregnancy (prior to delivery/birth)
Intervention | Participants (Count of Participants) |
---|---|
Intervention Arm | 352 |
Placebo Arm | 325 |
- Incidence of Perinatal Mortality (NCT02409680)
Timeframe: At delivery or at Day 42 after delivery
Intervention | Participants (Count of Participants) |
---|---|
Intervention Arm | 264 |
Placebo Arm | 309 |
The primary outcome of this study is incidence of preterm birth, which will be defined as delivery at or after 20 0/7 weeks and prior to 37 0/7 weeks. This will be determined based on actual date of delivery in comparison to the projected estimated due date (EDD), independent of whether or not the preterm delivery is indicated or spontaneous. (NCT02409680)
Timeframe: At delivery
Intervention | Participants (Count of Participants) |
---|---|
Intervention Arm | 668 |
Placebo Arm | 754 |
- Small for gestational age (SGA) as defined by the INTERGROWTH-21st standard (NCT02409680)
Timeframe: At delivery or at Day 42 after delivery
Intervention | Participants (Count of Participants) |
---|---|
Intervention Arm | 1506 |
Placebo Arm | 1564 |
- Vaginal bleeding (NCT02409680)
Timeframe: At delivery or at Day 42 after delivery
Intervention | Participants (Count of Participants) |
---|---|
Intervention Arm | 214 |
Placebo Arm | 246 |
- Antepartum hemorrhage (NCT02409680)
Timeframe: At delivery or at Day 42 after delivery
Intervention | Participants (Count of Participants) |
---|---|
Intervention Arm | 26 |
Placebo Arm | 25 |
- Postpartum hemorrhage (NCT02409680)
Timeframe: At delivery or at Day 42 after delivery
Intervention | Participants (Count of Participants) |
---|---|
Intervention Arm | 54 |
Placebo Arm | 43 |
- Incidence of Maternal Mortality (NCT02409680)
Timeframe: At delivery or at Day 42 after delivery
Intervention | Participants (Count of Participants) |
---|---|
Intervention Arm | 9 |
Placebo Arm | 12 |
- Incidence of Late Abortion (NCT02409680)
Timeframe: At delivery or at Day 42 after delivery
Intervention | Participants (Count of Participants) |
---|---|
Intervention Arm | 23 |
Placebo Arm | 30 |
Hemoglobin < 7.0 gm/dl at 26-30 weeks gestation or a drop of 3.5+ gm/dl from screening to 26-30 weeks gestation (NCT02409680)
Timeframe: At enrollment, 4 weeks post enrollment, and 26-30 weeks GA.
Intervention | Participants (Count of Participants) |
---|---|
Intervention Arm | 290 |
Placebo Arm | 333 |
Early preterm delivery (<34 weeks) and hypertensive disorders (i.e.: preeclampsia) (NCT02409680)
Timeframe: At delivery or at Day 42 after delivery
Intervention | Participants (Count of Participants) |
---|---|
Intervention Arm | 8 |
Placebo Arm | 21 |
51 reviews available for indomethacin and Infant, Premature, Diseases
Article | Year |
---|---|
The effectiveness of interventions to prevent intraventricular haemorrhage in premature infants: A systematic review and network meta-analysis.
Topics: Cerebral Hemorrhage; Humans; Indomethacin; Infant; Infant, Low Birth Weight; Infant, Newborn; Infant | 2023 |
Indomethacin for preterm infants with intracranial hemorrhage.
Topics: Cardiovascular Agents; Ductus Arteriosus, Patent; Humans; Indomethacin; Infant, Newborn; Infant, Pre | 2013 |
Therapeutic manipulation of the ductus arteriosus: current options and future prospects.
Topics: Ductus Arteriosus, Patent; Female; Forecasting; Hemodynamics; Humans; Ibuprofen; Indomethacin; Infan | 2014 |
Nursing Assessment, Education, and Care of Extremely Premature Neonates with Patent Ductus Arteriosus.
Topics: Cyclooxygenase Inhibitors; Ductus Arteriosus, Patent; Humans; Indomethacin; Infant, Extremely Low Bi | 2016 |
Surgical Intervention in Preterm Neonates with Patent Ductus Arteriosus.
Topics: Bronchopulmonary Dysplasia; Combined Modality Therapy; Cyclooxygenase Inhibitors; Ductus Arteriosus, | 2016 |
Understanding clinical literature relevant to spontaneous intestinal perforations.
Topics: Acute Disease; Bacterial Infections; Critical Care; Dexamethasone; Drug Therapy, Combination; Female | 2009 |
Therapeutic closure of the ductus arteriosus: benefits and limitations.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Ductus Arteriosus, Patent; Evidence-Based Medicine; Gestati | 2009 |
Nonsteroidal anti-inflammatory drugs (NSAIDs) in the newborn - which ones?
Topics: Anti-Inflammatory Agents, Non-Steroidal; Ductus Arteriosus, Patent; Hemorrhage; Humans; Ibuprofen; I | 2009 |
Treatment of persistent patent ductus arteriosus in preterm infants: time to accept the null hypothesis?
Topics: Anti-Inflammatory Agents, Non-Steroidal; Cardiac Surgical Procedures; Confidence Intervals; Ductus A | 2010 |
Prophylactic intravenous indomethacin for preventing mortality and morbidity in preterm infants.
Topics: Cardiovascular Agents; Cerebral Hemorrhage; Ductus Arteriosus, Patent; Humans; Indomethacin; Infant, | 2010 |
Network meta-analysis of indomethacin versus ibuprofen versus placebo for PDA in preterm infants.
Topics: Cardiovascular Agents; Cyclooxygenase Inhibitors; Ductus Arteriosus, Patent; Female; Humans; Ibuprof | 2011 |
Patent ductus arteriosus: wait and see?
Topics: Anti-Inflammatory Agents, Non-Steroidal; Ductus Arteriosus, Patent; Humans; Ibuprofen; Indomethacin; | 2011 |
Should we definitively abandon prophylaxis for patent ductus arteriosus in preterm new-borns?
Topics: Cyclooxygenase Inhibitors; Ductus Arteriosus, Patent; Humans; Ibuprofen; Indomethacin; Infant, Extre | 2011 |
Tocolytic therapy for acute preterm labor.
Topics: Calcium Channel Blockers; Drug Administration Schedule; Female; Gestational Age; Humans; Indomethaci | 2012 |
Tocolytic therapy for acute preterm labor.
Topics: Calcium Channel Blockers; Drug Administration Schedule; Female; Gestational Age; Humans; Indomethaci | 2012 |
Tocolytic therapy for acute preterm labor.
Topics: Calcium Channel Blockers; Drug Administration Schedule; Female; Gestational Age; Humans; Indomethaci | 2012 |
Tocolytic therapy for acute preterm labor.
Topics: Calcium Channel Blockers; Drug Administration Schedule; Female; Gestational Age; Humans; Indomethaci | 2012 |
The ductus arteriosus: a refined approach!
Topics: Biomarkers; Cyclooxygenase Inhibitors; Decision Making; Ductus Arteriosus, Patent; Echocardiography; | 2012 |
Managing the patent ductus arteriosus in the premature neonate: a new look at what we thought we knew.
Topics: Acetaminophen; Biomarkers; Dose-Response Relationship, Drug; Ductus Arteriosus, Patent; Echocardiogr | 2012 |
Patent ductus arteriosus: are current neonatal treatment options better or worse than no treatment at all?
Topics: Cardiovascular Agents; Ductus Arteriosus, Patent; Female; Humans; Indomethacin; Infant, Newborn; Inf | 2012 |
Segmental absence of intestinal musculature: an increasingly reported pathology.
Topics: Abdomen, Acute; Abnormalities, Multiple; Adult; Cesarean Section; Digestive System Abnormalities; Du | 2012 |
[Progresses in treatment of patent ductus arteriosus in premature infants].
Topics: Ductus Arteriosus; Ductus Arteriosus, Patent; Humans; Ibuprofen; Indomethacin; Infant, Low Birth Wei | 2012 |
Prophylactic intravenous indomethacin for preventing mortality and morbidity in preterm infants.
Topics: Cardiovascular Agents; Cerebral Hemorrhage; Ductus Arteriosus, Patent; Humans; Indomethacin; Infant, | 2002 |
Prophylactic indomethacin for preterm infants: a systematic review and meta-analysis.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Cerebral Hemorrhage; Humans; Indomethacin; Infant, Newborn; | 2003 |
Should a prolonged or short course of indomethacin be used in preterm infants to treat patent ductus arteriosus?
Topics: Cardiovascular Agents; Ductus Arteriosus, Patent; Humans; Indomethacin; Infant, Newborn; Infant, Pre | 2003 |
Prolonged versus short course of indomethacin for the treatment of patent ductus arteriosus in preterm infants.
Topics: Ductus Arteriosus, Patent; Humans; Indomethacin; Infant, Newborn; Infant, Premature; Infant, Prematu | 2004 |
[The pharmacological manipulation of Botallo's duct in the duct-dependent congenital cardiopathies and in the preterm infants with respiratory distress. A review and personal findings].
Topics: Alprostadil; Anti-Inflammatory Agents, Non-Steroidal; Cardiovascular Agents; Cerebral Angiography; C | 2005 |
Systematic review: intravenous Ibuprofen in preterm newborns.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Ductus Arteriosus, Patent; Female; Humans; Ibuprofen; Indom | 2006 |
Minimising neonatal brain injury: how research in the past five years has changed my clinical practice.
Topics: Animals; Birth Injuries; Brain Diseases; Dexamethasone; Disease Models, Animal; Ethamsylate; Humans; | 2007 |
Prolonged versus short course of indomethacin for the treatment of patent ductus arteriosus in preterm infants.
Topics: Ductus Arteriosus, Patent; Humans; Indomethacin; Infant, Newborn; Infant, Premature; Infant, Prematu | 2007 |
Metaanalysis of the effect of antenatal indomethacin on neonatal outcomes.
Topics: Enterocolitis, Necrotizing; Female; Humans; Indomethacin; Infant, Newborn; Infant, Premature; Infant | 2007 |
The ductus arteriosus: why and how to manipulate its patency.
Topics: Alprostadil; Ductus Arteriosus, Patent; Gestational Age; Heart Defects, Congenital; Humans; Indometh | 1983 |
[Patent ductus arteriosus in premature infants (review of the literature)].
Topics: Aortography; Carbon Dioxide; Digoxin; Diuretics; Ductus Arteriosus, Patent; Echocardiography; Electr | 1982 |
The problem of ductal patency in prematures.
Topics: Cardiac Catheterization; Digoxin; Ductus Arteriosus, Patent; Echocardiography; Electrocardiography; | 1981 |
Patent ductus arteriosus. Clinical relevance of prostaglandins and prostaglandin inhibitors in PDA pathophysiology and treatment.
Topics: Ductus Arteriosus; Ductus Arteriosus, Patent; Female; Humans; Indomethacin; Infant, Newborn; Infant, | 1995 |
Patent ductus arteriosus in the newborn.
Topics: Ductus Arteriosus, Patent; Humans; Indomethacin; Infant, Newborn; Infant, Premature; Infant, Prematu | 1993 |
Drug disposition in neonates with patent ductus arteriosus.
Topics: Absorption; Anti-Bacterial Agents; Digoxin; Ductus Arteriosus, Patent; Humans; Indomethacin; Infant, | 1993 |
Recommendations for the postnatal use of indomethacin: an analysis of four separate treatment strategies.
Topics: Ductus Arteriosus, Patent; Humans; Indomethacin; Infant, Newborn; Infant, Premature; Infant, Prematu | 1996 |
Patent ductus arteriosus in the preterm infant.
Topics: Cyclooxygenase Inhibitors; Ductus Arteriosus, Patent; Humans; Indomethacin; Infant, Newborn; Infant, | 1996 |
Routine indomethacin prophylaxis: has the time come?
Topics: Cerebral Hemorrhage; Cyclooxygenase Inhibitors; Humans; Indomethacin; Infant, Newborn; Infant, Prema | 1996 |
Intravenous indomethacin for preventing mortality and morbidity in very low birth weight infants.
Topics: Cardiovascular Agents; Cerebral Hemorrhage; Ductus Arteriosus, Patent; Humans; Indomethacin; Infant, | 2000 |
Furosemide for symptomatic patent ductus arteriosus in indomethacin-treated infants.
Topics: Cyclooxygenase Inhibitors; Diuretics; Ductus Arteriosus, Patent; Furosemide; Humans; Indomethacin; I | 2000 |
Furosemide for symptomatic patent ductus arteriosus in indomethacin-treated infants.
Topics: Cyclooxygenase Inhibitors; Diuretics; Ductus Arteriosus, Patent; Furosemide; Humans; Indomethacin; I | 2001 |
[Drug therapy of patent ductus arteriosus in premature and newborn infants].
Topics: Apnea; Aspirin; Chloroquine; Digitalis Glycosides; Ductus Arteriosus, Patent; Humans; Indomethacin; | 1978 |
The patent ductus arteriosus.
Topics: Acute Kidney Injury; Animals; Clinical Trials as Topic; Ductus Arteriosus; Ductus Arteriosus, Patent | 1978 |
[Pathogenic factors in bronchopulmonary dysplasia].
Topics: Birth Weight; Bronchopulmonary Dysplasia; Gestational Age; Humans; Iatrogenic Disease; Indomethacin; | 1991 |
Indomethacin for prevention of neonatal intraventricular hemorrhage.
Topics: Birth Weight; Cerebral Hemorrhage; Cerebral Ventricles; Female; Humans; Indomethacin; Infant, Newbor | 1991 |
Intraventricular hemorrhage in the premature infant--current concepts. Part II.
Topics: Cerebral Hemorrhage; Cerebral Ventricles; Combined Modality Therapy; Echoencephalography; Ethamsylat | 1989 |
Oligohydramnios, renal insufficiency, and ileal perforation in preterm infants after intrauterine exposure to indomethacin.
Topics: Amniotic Fluid; Female; Gastrointestinal Hemorrhage; Humans; Ileal Diseases; Indomethacin; Infant, L | 1988 |
The relationship of symptomatic patent ductus arteriosus to respiratory distress in premature newborn infants.
Topics: Ductus Arteriosus, Patent; Humans; Indomethacin; Infant, Newborn; Infant, Premature, Diseases; Ligat | 1987 |
Prevention of neonatal intraventricular hemorrhage.
Topics: Cerebral Hemorrhage; Cerebral Ventricles; Cerebrovascular Circulation; Ethamsylate; Humans; Indometh | 1987 |
Therapeutic interventions to prevent intracerebral hemorrhage in preterm infants.
Topics: Cerebral Hemorrhage; Cerebrovascular Circulation; Clinical Trials as Topic; Ethamsylate; Humans; Ind | 1986 |
Patent ductus arteriosus in the neonate.
Topics: Alprostadil; Blood Circulation; Clinical Trials as Topic; Digoxin; Ductus Arteriosus; Ductus Arterio | 1986 |
Patent ductus arteriosus in the premature neonate.
Topics: Ductus Arteriosus, Patent; Humans; Indomethacin; Infant, Newborn; Infant, Premature, Diseases; Ligat | 1985 |
69 trials available for indomethacin and Infant, Premature, Diseases
Article | Year |
---|---|
Effect of Prophylactic Indomethacin in Extremely Low Birth Weight Infants Based on the Predicted Risk of Severe Intraventricular Hemorrhage.
Topics: Birth Weight; Cerebral Hemorrhage; Cyclooxygenase Inhibitors; Drug Administration Schedule; Female; | 2018 |
A randomised placebo-controlled trial of early treatment of the patent ductus arteriosus.
Topics: Brain; Cyclooxygenase Inhibitors; Double-Blind Method; Ductus Arteriosus, Patent; Echocardiography, | 2014 |
A Comparison of Early Ibuprofen and Indomethacin Administration to Prevent Intraventricular Hemorrhage Among Preterm Infants.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Cerebral Hemorrhage; Cyclooxygenase Inhibitors; Ductus Arte | 2016 |
Pharmacological closure of patent ductus arteriosus: effects on pulse pressure and on endothelin-1 and vasopressin excretion.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Arginine Vasopressin; Blood Pressure; Ductus Arteriosus, Pa | 2008 |
B-type natriuretic peptide concentrations to guide treatment of patent ductus arteriosus.
Topics: Biomarkers; Cyclooxygenase Inhibitors; Ductus Arteriosus, Patent; Echocardiography; Female; Humans; | 2009 |
Lasting effects of preterm birth and neonatal brain hemorrhage at 12 years of age.
Topics: Brain Damage, Chronic; Cerebral Ventricles; Child; Child Behavior Disorders; Child, Preschool; Cogni | 2009 |
Trajectories of receptive language development from 3 to 12 years of age for very preterm children.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Brain Damage, Chronic; Cerebral Hemorrhage; Child; Child, P | 2009 |
Duration of indomethacin treatment of the preterm patent ductus arteriosus as directed by echocardiography.
Topics: Cyclooxygenase Inhibitors; Drug Administration Schedule; Ductus Arteriosus, Patent; Echocardiography | 2009 |
Effect of indomethacin infused over 30 minutes on cerebral fractional tissue oxygen extraction in preterm newborns with a patent ductus arteriosus.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Cause of Death; Cerebrum; Ductus Arteriosus, Patent; Female | 2010 |
Effects of prophylactic indomethacin in extremely low-birth-weight infants with and without adequate exposure to antenatal corticosteroids.
Topics: Adrenal Cortex Hormones; Anti-Inflammatory Agents, Non-Steroidal; Developmental Disabilities; Female | 2011 |
Effects of prophylactic indomethacin on renal and intestinal blood flows in premature infants.
Topics: Cerebral Hemorrhage; Ductus Arteriosus, Patent; Female; Humans; Indomethacin; Infant, Newborn; Infan | 2012 |
Ibuprofen prophylaxis in preterm neonates.
Topics: Cyclooxygenase Inhibitors; Ductus Arteriosus, Patent; Humans; Hypertension, Pulmonary; Hypoxia; Ibup | 2002 |
Oral ibuprofen and indomethacin for treatment of patent ductus arteriosus in premature infants: a randomized trial at Ramathibodi Hospital.
Topics: Administration, Oral; Anti-Inflammatory Agents, Non-Steroidal; Ductus Arteriosus, Patent; Female; Hu | 2002 |
Impact of bronchopulmonary dysplasia, brain injury, and severe retinopathy on the outcome of extremely low-birth-weight infants at 18 months: results from the trial of indomethacin prophylaxis in preterms.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Blindness; Brain Diseases; Bronchopulmonary Dysplasia; Cere | 2003 |
Impact of bronchopulmonary dysplasia, brain injury, and severe retinopathy on the outcome of extremely low-birth-weight infants at 18 months: results from the trial of indomethacin prophylaxis in preterms.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Blindness; Brain Diseases; Bronchopulmonary Dysplasia; Cere | 2003 |
Impact of bronchopulmonary dysplasia, brain injury, and severe retinopathy on the outcome of extremely low-birth-weight infants at 18 months: results from the trial of indomethacin prophylaxis in preterms.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Blindness; Brain Diseases; Bronchopulmonary Dysplasia; Cere | 2003 |
Impact of bronchopulmonary dysplasia, brain injury, and severe retinopathy on the outcome of extremely low-birth-weight infants at 18 months: results from the trial of indomethacin prophylaxis in preterms.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Blindness; Brain Diseases; Bronchopulmonary Dysplasia; Cere | 2003 |
Impact of bronchopulmonary dysplasia, brain injury, and severe retinopathy on the outcome of extremely low-birth-weight infants at 18 months: results from the trial of indomethacin prophylaxis in preterms.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Blindness; Brain Diseases; Bronchopulmonary Dysplasia; Cere | 2003 |
Impact of bronchopulmonary dysplasia, brain injury, and severe retinopathy on the outcome of extremely low-birth-weight infants at 18 months: results from the trial of indomethacin prophylaxis in preterms.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Blindness; Brain Diseases; Bronchopulmonary Dysplasia; Cere | 2003 |
Impact of bronchopulmonary dysplasia, brain injury, and severe retinopathy on the outcome of extremely low-birth-weight infants at 18 months: results from the trial of indomethacin prophylaxis in preterms.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Blindness; Brain Diseases; Bronchopulmonary Dysplasia; Cere | 2003 |
Impact of bronchopulmonary dysplasia, brain injury, and severe retinopathy on the outcome of extremely low-birth-weight infants at 18 months: results from the trial of indomethacin prophylaxis in preterms.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Blindness; Brain Diseases; Bronchopulmonary Dysplasia; Cere | 2003 |
Impact of bronchopulmonary dysplasia, brain injury, and severe retinopathy on the outcome of extremely low-birth-weight infants at 18 months: results from the trial of indomethacin prophylaxis in preterms.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Blindness; Brain Diseases; Bronchopulmonary Dysplasia; Cere | 2003 |
Impact of bronchopulmonary dysplasia, brain injury, and severe retinopathy on the outcome of extremely low-birth-weight infants at 18 months: results from the trial of indomethacin prophylaxis in preterms.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Blindness; Brain Diseases; Bronchopulmonary Dysplasia; Cere | 2003 |
Impact of bronchopulmonary dysplasia, brain injury, and severe retinopathy on the outcome of extremely low-birth-weight infants at 18 months: results from the trial of indomethacin prophylaxis in preterms.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Blindness; Brain Diseases; Bronchopulmonary Dysplasia; Cere | 2003 |
Impact of bronchopulmonary dysplasia, brain injury, and severe retinopathy on the outcome of extremely low-birth-weight infants at 18 months: results from the trial of indomethacin prophylaxis in preterms.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Blindness; Brain Diseases; Bronchopulmonary Dysplasia; Cere | 2003 |
Impact of bronchopulmonary dysplasia, brain injury, and severe retinopathy on the outcome of extremely low-birth-weight infants at 18 months: results from the trial of indomethacin prophylaxis in preterms.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Blindness; Brain Diseases; Bronchopulmonary Dysplasia; Cere | 2003 |
Impact of bronchopulmonary dysplasia, brain injury, and severe retinopathy on the outcome of extremely low-birth-weight infants at 18 months: results from the trial of indomethacin prophylaxis in preterms.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Blindness; Brain Diseases; Bronchopulmonary Dysplasia; Cere | 2003 |
Impact of bronchopulmonary dysplasia, brain injury, and severe retinopathy on the outcome of extremely low-birth-weight infants at 18 months: results from the trial of indomethacin prophylaxis in preterms.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Blindness; Brain Diseases; Bronchopulmonary Dysplasia; Cere | 2003 |
Impact of bronchopulmonary dysplasia, brain injury, and severe retinopathy on the outcome of extremely low-birth-weight infants at 18 months: results from the trial of indomethacin prophylaxis in preterms.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Blindness; Brain Diseases; Bronchopulmonary Dysplasia; Cere | 2003 |
Randomized trial of prolonged low-dose versus conventional-dose indomethacin for treating patent ductus arteriosus in very low birth weight infants.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Drug Administration Schedule; Ductus Arteriosus, Patent; Ec | 2003 |
Effect of early targeted indomethacin on the ductus arteriosus and blood flow to the upper body and brain in the preterm infant.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Cerebral Hemorrhage; Cerebrovascular Circulation; Cross-Ove | 2003 |
Comparison of ibuprofen and indomethacin therapy for patent ductus arteriosus in preterm infants.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Cyclooxygenase Inhibitors; Ductus Arteriosus, Patent; Femal | 2003 |
A comparison of oral ibuprofen and intravenous indomethacin for closure of patent ductus arteriosus in preterm infants.
Topics: Administration, Oral; Cyclooxygenase Inhibitors; Ductus Arteriosus, Patent; Female; Humans; Ibuprofe | 2003 |
[Ibuprofen versus indomethacin in the treatment of patent ductus arteriosus in preterm infants].
Topics: Anti-Inflammatory Agents, Non-Steroidal; Ductus Arteriosus, Patent; Female; Humans; Ibuprofen; Indom | 2005 |
Combined treatment with a nonselective nitric oxide synthase inhibitor (l-NMMA) and indomethacin increases ductus constriction in extremely premature newborns.
Topics: Drug Therapy, Combination; Ductus Arteriosus; Ductus Arteriosus, Patent; Enzyme Inhibitors; Female; | 2005 |
Comparison of ibuprofen and indometacin for early-targeted treatment of patent ductus arteriosus in extremely premature infants: a randomised controlled trial.
Topics: Analysis of Variance; Cyclooxygenase Inhibitors; Dose-Response Relationship, Drug; Ductus Arteriosus | 2008 |
Decreased plasma glucose after indomethacin therapy in premature infants with patent ductus anteriosus.
Topics: Blood Glucose; Clinical Trials as Topic; Double-Blind Method; Ductus Arteriosus, Patent; Humans; Ind | 1982 |
Early closure of patent ductus arteriosus with indomethacin in preterm infants with idiopathic respiratory distress syndrome.
Topics: Clinical Trials as Topic; Ductus Arteriosus, Patent; Humans; Indomethacin; Infant, Newborn; Infant, | 1983 |
Effects of indomethacin in premature infants with patent ductus arteriosus: results of a national collaborative study.
Topics: Clinical Trials as Topic; Ductus Arteriosus, Patent; Humans; Indomethacin; Infant, Newborn; Infant, | 1983 |
Effects of indomethacin in premature infants with patent ductus arteriosus: results of a national collaborative study.
Topics: Clinical Trials as Topic; Ductus Arteriosus, Patent; Humans; Indomethacin; Infant, Newborn; Infant, | 1983 |
Effects of indomethacin in premature infants with patent ductus arteriosus: results of a national collaborative study.
Topics: Clinical Trials as Topic; Ductus Arteriosus, Patent; Humans; Indomethacin; Infant, Newborn; Infant, | 1983 |
Effects of indomethacin in premature infants with patent ductus arteriosus: results of a national collaborative study.
Topics: Clinical Trials as Topic; Ductus Arteriosus, Patent; Humans; Indomethacin; Infant, Newborn; Infant, | 1983 |
Retinopathy of prematurity (ROP) and indomethacin therapy in premature infants with patent ductus arteriosus (PDA).
Topics: Clinical Trials as Topic; Ductus Arteriosus, Patent; Gestational Age; Humans; Indomethacin; Infant, | 1983 |
[Controlled trial of intravenous lyophilized indomethacin in the treatment of persistent ductus arteriosus in premature infants].
Topics: Clinical Trials as Topic; Ductus Arteriosus, Patent; Female; Humans; Indomethacin; Infant, Newborn; | 1983 |
Surgical closure of patent ductus arteriosus in 268 preterm infants.
Topics: Clinical Trials as Topic; Double-Blind Method; Ductus Arteriosus, Patent; Female; Humans; Indomethac | 1984 |
Clinical course to 1 year of age in premature infants with patent ductus arteriosus: results of a multicenter randomized trial of indomethacin.
Topics: Bronchopulmonary Dysplasia; Child Development; Clinical Trials as Topic; Combined Modality Therapy; | 1984 |
The use of dopamine for the prevention of the renal side effects of indomethacin in premature infants with patent ductus arteriosus.
Topics: Clinical Trials as Topic; Dopamine; Ductus Arteriosus, Patent; Humans; Indomethacin; Infant, Newborn | 1984 |
Mannheimer lecture.
Topics: Clinical Trials as Topic; Ductus Arteriosus, Patent; Humans; Indomethacin; Infant, Newborn; Infant, | 1982 |
Decreased plasma glucose following indomethacin therapy in premature infants with patent ductus arteriosus.
Topics: Blood Glucose; Ductus Arteriosus, Patent; Humans; Indomethacin; Infant, Newborn; Infant, Premature, | 1982 |
Indomethacin treatment for symptomatic patent ductus arteriosus: a double-blind control study.
Topics: Clinical Trials as Topic; Double-Blind Method; Ductus Arteriosus, Patent; Gastrointestinal Hemorrhag | 1981 |
Prophylactic indomethacin therapy for patent ductus arteriosus in very-low-birth-weight infants.
Topics: Clinical Trials as Topic; Double-Blind Method; Ductus Arteriosus, Patent; Female; Hemodynamics; Huma | 1982 |
Indomethacin for closure of patent ductus arteriosus in prematures.
Topics: Clinical Trials as Topic; Double-Blind Method; Ductus Arteriosus, Patent; Enterocolitis, Pseudomembr | 1982 |
Furosemide prevents the renal side effects of indomethacin therapy in premature infants with patent ductus arteriosus.
Topics: Drug Therapy, Combination; Ductus Arteriosus, Patent; Furosemide; Humans; Indomethacin; Infant, Newb | 1982 |
Intravenous indomethacin therapy in premature infants with patent ductus arteriosus. Causes of death and one-year follow-up.
Topics: Double-Blind Method; Ductus Arteriosus, Patent; Follow-Up Studies; Humans; Indomethacin; Infant, New | 1982 |
Improved lung compliance following indomethacin therapy in premature infants with persistent ductus arteriosus.
Topics: Birth Weight; Blood Gas Analysis; Gestational Age; Humans; Hydrogen-Ion Concentration; Indomethacin; | 1981 |
A double blind study of the effects of oral indomethacin in preterm infants with patent ductus arteriosus who failed medical management.
Topics: Double-Blind Method; Drug Evaluation; Ductus Arteriosus, Patent; Humans; Indomethacin; Infant, Newbo | 1981 |
Tocolysis in advanced preterm labor: impact on neonatal outcome.
Topics: Cohort Studies; Female; Humans; Indomethacin; Infant, Newborn; Infant, Premature, Diseases; Magnesiu | 1995 |
Continuous versus multiple rapid infusions of indomethacin: effects on cerebral blood flow velocity.
Topics: Blood Flow Velocity; Cerebrovascular Circulation; Depression, Chemical; Ductus Arteriosus, Patent; E | 1995 |
Antenatal steroids, delivery mode, and intraventricular hemorrhage in preterm infants.
Topics: Cerebral Hemorrhage; Cesarean Section; Female; Humans; Indomethacin; Infant, Low Birth Weight; Infan | 1995 |
Effects of repeated indomethacin administration on cerebral oxygenation and haemodynamics in preterm infants: combined near infrared spectrophotometry and Doppler ultrasound study.
Topics: Blood Flow Velocity; Brain; Cerebrovascular Circulation; Ductus Arteriosus, Patent; Female; Humans; | 1994 |
Low-dose indomethacin therapy and extension of intraventricular hemorrhage: a multicenter randomized trial.
Topics: Cerebral Hemorrhage; Drug Administration Schedule; Ductus Arteriosus, Patent; Female; Humans; Indome | 1994 |
Risk period for intraventricular hemorrhage of the preterm neonate is independent of gestational age.
Topics: Age of Onset; Cerebral Hemorrhage; Cerebral Ventricles; Gestational Age; Humans; Indomethacin; Infan | 1993 |
Prophylactic indomethacin therapy in the first twenty-four hours of life for the prevention of patent ductus arteriosus in preterm infants treated prophylactically with surfactant in the delivery room.
Topics: Birth Weight; Ductus Arteriosus, Patent; Electrocardiography; Female; Humans; Indomethacin; Infant, | 1996 |
Increased risk of necrotizing enterocolitis in premature infants with patent ductus arteriosus treated with indomethacin.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Ductus Arteriosus, Patent; Enterocolitis, Pseudomembranous; | 1996 |
Neurodevelopmental outcome at 36 months' corrected age of preterm infants in the Multicenter Indomethacin Intraventricular Hemorrhage Prevention Trial.
Topics: Cerebral Hemorrhage; Chi-Square Distribution; Child Development; Child, Preschool; Cyclooxygenase In | 1996 |
Comparative evaluation of the effects of indomethacin and ibuprofen on cerebral perfusion and oxygenation in preterm infants with patent ductus arteriosus.
Topics: Blood Flow Velocity; Brain; Cerebrovascular Circulation; Cyclooxygenase Inhibitors; Dose-Response Re | 1997 |
Cognitive outcome at 4 1/2 years of very low birth weight infants enrolled in the multicenter indomethacin intraventricular hemorrhage prevention trial.
Topics: Brain Damage, Chronic; Cerebral Hemorrhage; Cerebral Ventricles; Child, Preschool; Cyclooxygenase In | 1998 |
Short versus prolonged indomethacin therapy for patent ductus arteriosus in preterm infants.
Topics: Cyclooxygenase Inhibitors; Ductus Arteriosus, Patent; Echocardiography; Gestational Age; Humans; Ind | 1999 |
Outcome of children in the indomethacin intraventricular hemorrhage prevention trial.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Brain Damage, Chronic; Cerebral Hemorrhage; Cerebral Ventri | 2000 |
Prophylactic indomethacin: factors determining permanent ductus arteriosus closure.
Topics: Cardiovascular Agents; Ductus Arteriosus, Patent; Female; Humans; Indomethacin; Infant, Newborn; Inf | 2000 |
Indomethacin prophylaxis for patent ductus arteriosus (PDA) in infants with a birth weight of less than 1250 grams.
Topics: Cyclooxygenase Inhibitors; Ductus Arteriosus, Patent; Female; Humans; Indomethacin; Infant, Newborn; | 1999 |
A comparison of ibuprofen and indomethacin for closure of patent ductus arteriosus.
Topics: Cyclooxygenase Inhibitors; Ductus Arteriosus, Patent; Humans; Ibuprofen; Indomethacin; Infant, Newbo | 2000 |
Early versus late indomethacin treatment for patent ductus arteriosus in premature infants with respiratory distress syndrome.
Topics: Ductus Arteriosus, Patent; Humans; Indomethacin; Infant, Newborn; Infant, Premature, Diseases; Injec | 2001 |
The use of indomethacin for the prevention of intraventricular brain hemorrhage in high-risk neonates.
Topics: Birth Weight; Cerebral Hemorrhage; Cerebral Ventricles; Cohort Studies; Gestational Age; Humans; Inc | 2000 |
Changes in cerebral, renal and mesenteric blood flow velocity during continuous and bolus infusion of indomethacin.
Topics: Blood Flow Velocity; Cerebrovascular Circulation; Cyclooxygenase Inhibitors; Ductus Arteriosus, Pate | 2002 |
The patent ductus arteriosus.
Topics: Acute Kidney Injury; Animals; Clinical Trials as Topic; Ductus Arteriosus; Ductus Arteriosus, Patent | 1978 |
[Indomethacin in the prevention of subependymal-intraventricular hemorrhage in preterm newborns with conventional mechanical ventilation].
Topics: Cerebral Hemorrhage; Double-Blind Method; Ependyma; Humans; Indomethacin; Infant, Newborn; Infant, P | 1992 |
Intravenous indomethacin therapy in preterm neonates with patent ductus arteriosus.
Topics: Ductus Arteriosus, Patent; Echocardiography, Doppler; Humans; Indomethacin; Infant, Newborn; Infant, | 1991 |
Symptomatic patent ductus arteriosus following prophylactic indomethacin. A clinical and biochemical appraisal.
Topics: Dinoprostone; Ductus Arteriosus, Patent; Epoprostenol; High-Frequency Ventilation; Humans; Indometha | 1991 |
Effects of indomethacin on cerebral haemodynamics in very preterm infants.
Topics: Blood Gas Monitoring, Transcutaneous; Blood Pressure; Blood Volume; Cerebrovascular Circulation; Dru | 1990 |
[Treatment of patent ductus arteriosus in premature infants by indomethacin].
Topics: Diuresis; Ductus Arteriosus, Patent; Humans; Indomethacin; Infant, Newborn; Infant, Premature, Disea | 1987 |
[Effects of early therapy with indomethacin on the manifestation of a persistent ductus arteriosus in extremely underweight premature infants].
Topics: Birth Weight; Clinical Trials as Topic; Drug Administration Schedule; Ductus Arteriosus, Patent; Fem | 1988 |
Prophylactic indomethacin for prevention of intraventricular hemorrhage in premature infants.
Topics: Birth Weight; Cerebral Hemorrhage; Ductus Arteriosus, Patent; Female; Humans; Indomethacin; Infant, | 1988 |
Therapeutic interventions to prevent intracerebral hemorrhage in preterm infants.
Topics: Cerebral Hemorrhage; Cerebrovascular Circulation; Clinical Trials as Topic; Ethamsylate; Humans; Ind | 1986 |
Early administration of indomethacin to preterm infants.
Topics: 6-Ketoprostaglandin F1 alpha; Clinical Trials as Topic; Double-Blind Method; Drug Administration Sch | 1986 |
Patent ductus arteriosus in the neonate.
Topics: Alprostadil; Blood Circulation; Clinical Trials as Topic; Digoxin; Ductus Arteriosus; Ductus Arterio | 1986 |
Randomized indomethacin trial for prevention of intraventricular hemorrhage in very low birth weight infants.
Topics: 6-Ketoprostaglandin F1 alpha; Cerebral Hemorrhage; Clinical Trials as Topic; Ductus Arteriosus, Pate | 1985 |
203 other studies available for indomethacin and Infant, Premature, Diseases
Article | Year |
---|---|
Effects of prophylactic indomethacin on intraventricular hemorrhage and adverse outcomes in neonatal intensive care unit.
Topics: Cerebral Hemorrhage; Child; Gestational Age; Humans; Indomethacin; Infant; Infant, Extremely Prematu | 2022 |
Neurodevelopment at 5 Years of Age According to Early Screening for Patent Ductus Arteriosus in Extremely Preterm Infants.
Topics: Child Development; Child, Preschool; Ductus Arteriosus, Patent; Humans; Indomethacin; Infant, Extrem | 2022 |
Management of patent ductus arteriosus in very preterm infants in England and Wales: a retrospective cohort study.
Topics: Ductus Arteriosus, Patent; Female; Fetal Growth Retardation; Humans; Ibuprofen; Indomethacin; Infant | 2022 |
Indomethacin dosing strategy and neonatal patent ductus arteriosus closure.
Topics: Cyclooxygenase Inhibitors; Dose-Response Relationship, Drug; Ductus Arteriosus, Patent; Female; Gest | 2019 |
Intensive and prolonged urine collection in preterm infants reveals three distinct indomethacin metabolic patterns: potential implications for drug dosing.
Topics: Drug Administration Schedule; Ductus Arteriosus, Patent; Female; Glucuronides; Humans; Indomethacin; | 2018 |
Does Postmenstrual Age Affect Medical Patent Ductus Arteriosus Treatment Success in Preterm Infants?
Topics: Anti-Inflammatory Agents, Non-Steroidal; Ductus Arteriosus, Patent; Female; Gestational Age; Humans; | 2019 |
Effectiveness and Renal Functions Safety of Treatments Used for Neonates with Patent Ductus Arteriosus: A Prospective Cohort Study.
Topics: Acetaminophen; Acute Kidney Injury; China; Cohort Studies; Ductus Arteriosus, Patent; Female; Humans | 2019 |
Optimal timing of video-assisted thoracoscopic surgery for patent ductus arteriosus in preterm infants born at ≤ 28 weeks of gestation.
Topics: Age Factors; Cardiovascular Agents; Ductus Arteriosus, Patent; Female; Humans; Indomethacin; Infant, | 2019 |
Vascular endothelial growth factor polymorphism rs2010963 status does not affect patent ductus arteriosus incidence or cyclooxygenase inhibitor treatment success in preterm infants.
Topics: Case-Control Studies; Cyclooxygenase Inhibitors; Ductus Arteriosus, Patent; Female; Humans; Ibuprofe | 2019 |
Tocolytic indomethacin: effects on neonatal haemodynamics and cerebral autoregulation in the preterm newborn.
Topics: Brain; Case-Control Studies; Cerebrovascular Circulation; Female; Gestational Age; Hemodynamics; Hom | 2013 |
Indomethacin prophylaxis to prevent intraventricular hemorrhage: association between incidence and timing of drug administration.
Topics: Cerebral Hemorrhage; Cyclooxygenase Inhibitors; Drug Administration Schedule; Female; Follow-Up Stud | 2013 |
Bartter syndrome: presentation in an extremely premature neonate.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Bartter Syndrome; Female; Humans; Indomethacin; Infant, Ext | 2013 |
Preoperative left ventricular internal dimension in end-diastole as earlier identification of early patent ductus arteriosus operation and postoperative intensive care in very low birth weight infants.
Topics: Cohort Studies; Ductus Arteriosus, Patent; Gestational Age; Heart Ventricles; Humans; Indomethacin; | 2013 |
Novel treatment criteria for persistent ductus arteriosus in neonates.
Topics: Cardiovascular Agents; Ductus Arteriosus, Patent; Echocardiography; Female; Heart Ventricles; Humans | 2014 |
Variation and comparative effectiveness of patent ductus arteriosus pharmacotherapy in extremely low birth weight infants.
Topics: Cohort Studies; Cyclooxygenase Inhibitors; Ductus Arteriosus, Patent; Female; Humans; Ibuprofen; Ind | 2014 |
Indomethacin-Responsive Patent Ductus Arteriosus in an Extremely Preterm Infant at 8 Weeks Postnatal Age.
Topics: Cyclooxygenase Inhibitors; Ductus Arteriosus, Patent; Humans; Indomethacin; Infant; Infant, Extremel | 2015 |
Postnatal Steroids and Febrile Seizure Susceptibility in Preterm Children.
Topics: Adrenal Cortex Hormones; Child, Preschool; Disease Susceptibility; Epilepsy; Female; Gestational Age | 2016 |
Editorial: Patent Ductus Arteriosus in Extremely Premature Neonates.
Topics: Anterior Cerebral Artery; Cyclooxygenase Inhibitors; Ductus Arteriosus, Patent; Echocardiography, Do | 2016 |
Quality Improvement Initiative to Reduce the Necrotizing Enterocolitis Rate in Premature Infants.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Blood Transfusion; Enterocolitis, Necrotizing; Humans; Inci | 2016 |
The effect of ductal diameter on surgical and medical closure of patent ductus arteriosus in preterm neonates.
Topics: Cardiovascular Surgical Procedures; Cyclooxygenase Inhibitors; Ductus Arteriosus; Ductus Arteriosus, | 2008 |
Chorioamnionitis and ontogeny of circulating prostaglandin and thromboxane in preterm infants.
Topics: Adolescent; Adult; Anti-Inflammatory Agents, Non-Steroidal; Birth Weight; Bronchopulmonary Dysplasia | 2008 |
[Drug therapy of persistent ductus arteriosus Botalli in the premature infant from the nursing viewpoint].
Topics: Anti-Inflammatory Agents, Non-Steroidal; Blood Pressure; Ductus Arteriosus, Patent; Echocardiography | 2008 |
[Neonatal Bartter syndrome's special features in very premature newborns].
Topics: Age Factors; Anti-Inflammatory Agents, Non-Steroidal; Bartter Syndrome; Dietary Supplements; Female; | 2009 |
[First SIBEN clinical consensus: diagnostic and therapeutic approach to patent ductus arteriosus in premature newborns].
Topics: Age Factors; Brain Diseases; Cost-Benefit Analysis; Cyclooxygenase Inhibitors; Diuretics; Ductus Art | 2008 |
Early or late surgical ligation of medical refractory patent ductus arteriosus in premature infants.
Topics: Cyclooxygenase Inhibitors; Ductus Arteriosus, Patent; Female; Gestational Age; Humans; Indomethacin; | 2009 |
Treatment of the patent ductus arteriosus: when, how, and for how long?
Topics: Cyclooxygenase Inhibitors; Drug Administration Schedule; Ductus Arteriosus, Patent; Humans; Indometh | 2009 |
Feeding practices and patent ductus arteriosus ligation preferences-are they related?
Topics: Anti-Inflammatory Agents, Non-Steroidal; Birth Weight; Ductus Arteriosus, Patent; Enteral Nutrition; | 2010 |
How useful are B-type natriuretic peptide measurements for monitoring changes in patent ductus arteriosus shunt magnitude?
Topics: Cardiovascular Agents; Ductus Arteriosus, Patent; Echocardiography; Female; Gestational Age; Humans; | 2010 |
Antenatal magnesium sulfate and the postnatal response of the ductus arteriosus to indomethacin in extremely preterm neonates.
Topics: Drug Administration Schedule; Ductus Arteriosus; Ductus Arteriosus, Patent; Female; Gestational Age; | 2011 |
Global shortage and rationing of indomethacin: need to refine approach.
Topics: Ductus Arteriosus, Patent; Global Health; Health Care Rationing; Humans; Indomethacin; Infant, Newbo | 2010 |
Use of echocardiography to guide the duration of indomethacin treatment of patent ductus arteriosus in preterm infants.
Topics: Cyclooxygenase Inhibitors; Ductus Arteriosus, Patent; Echocardiography; Gestational Age; Humans; Ind | 2010 |
Comparison of two neonatal indomethacin protocols: efficacy and outcome for patent ductus arteriosus closure.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Birth Weight; Ductus Arteriosus, Patent; Female; Gestationa | 2010 |
Urinary aquaporin-2 excretion during ibuprofen or indomethacin treatment in preterm infants with patent ductus arteriosus.
Topics: Aquaporin 2; Cardiovascular Agents; Ductus Arteriosus, Patent; Female; Gestational Age; Humans; Ibup | 2011 |
Why would a sane clinician not prescribe prophylactic indomethacin?
Topics: Anti-Inflammatory Agents, Non-Steroidal; Cardiovascular Agents; Clinical Trials as Topic; Ductus Art | 2011 |
Patent ductus arteriosus in the preterm infant: a survey of clinical practices in French neonatal intensive care units.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Contraindications; Data Collection; Dose-Response Relations | 2011 |
The risk of necrotizing enterocolitis after indomethacin tocolysis.
Topics: Cohort Studies; Enterocolitis, Necrotizing; Female; Humans; Indomethacin; Infant, Newborn; Infant, P | 2011 |
Indomethacin in pregnancy: applications and safety.
Topics: Cerclage, Cervical; Cerebral Hemorrhage; Ductus Arteriosus; Enterocolitis, Necrotizing; Female; Fetu | 2012 |
Update on management of patent ductus arteriosus in the preterm infant.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Ductus Arteriosus, Patent; Humans; Ibuprofen; Indomethacin; | 2011 |
Prophylactic indomethacin infusion increases fractional cerebral oxygen extraction in ELBW neonates.
Topics: Brain; Carbon Dioxide; Cerebral Ventricles; Cerebrovascular Circulation; Cyclooxygenase Inhibitors; | 2012 |
Failure of a repeat course of cyclooxygenase inhibitor to close a PDA is a risk factor for developing chronic lung disease in ELBW infants.
Topics: Chronic Disease; Cyclooxygenase Inhibitors; Drug Administration Schedule; Ductus Arteriosus, Patent; | 2012 |
Patent ductus arteriosus in infants <29 weeks gestation--outcomes and factors affecting closure.
Topics: Cardiovascular Agents; Ductus Arteriosus, Patent; Female; Humans; Indomethacin; Infant, Extremely Pr | 2012 |
Does treatment of patent ductus arteriosus with cyclooxygenase inhibitors affect neonatal regional tissue oxygenation?
Topics: Analysis of Variance; Blood Gas Analysis; Cerebrovascular Circulation; Chi-Square Distribution; Chro | 2012 |
Spontaneous intestinal perforation in extremely low birth weight infants: association with indometacin therapy and effects on neurodevelopmental outcomes at 18-22 months corrected age.
Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Developmental Disabilities; Ductus Arteriosus, Paten | 2013 |
Neurodevelopmental outcomes following two different treatment approaches (early ligation and selective ligation) for patent ductus arteriosus.
Topics: Age Factors; Blindness; Cardiovascular Agents; Cerebral Palsy; Child, Preschool; Combined Modality T | 2012 |
Decline in health status of extremely premature neonates with patent ductus arteriosus after second course of medical therapy.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Cardiac Surgical Procedures; Ductus Arteriosus, Patent; Hea | 2013 |
Effectiveness and safety of indomethacin versus ibuprofen for the treatment of patent ductus arteriosus in preterm infants.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Ductus Arteriosus, Patent; Enterocolitis, Necrotizing; Fema | 2013 |
Change in cognitive function over time in very low-birth-weight infants.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Brain Damage, Chronic; Cerebral Hemorrhage; Child; Child, P | 2003 |
Safety and efficacy of ibuprofen versus indomethacin in preterm infants.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Humans; Ibuprofen; Indomethacin; Infant, Newborn; Infant, P | 2003 |
Persistent Doppler flow predicts lack of response to multiple courses of indomethacin in premature infants with recurrent patent ductus arteriosus.
Topics: Ductus Arteriosus, Patent; Echocardiography, Doppler, Color; Hemodynamics; Humans; Indomethacin; Inf | 2003 |
Indomethacin responsiveness of patent ductus arteriosus and renal abnormalities in preterm infants treated with indomethacin.
Topics: Cardiovascular Agents; Chorioamnionitis; Ductus Arteriosus, Patent; Echocardiography, Doppler; Femal | 2003 |
Tolerance to early human milk feeding is not compromised by indomethacin in preterm infants with persistent ductus arteriosus.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Ductus Arteriosus, Patent; Enteral Nutrition; Female; Human | 2003 |
Patent ductus arteriosus, indomethacin and necrotizing enterocolitis in very low birth weight infants: a population-based study.
Topics: Cardiovascular Agents; Ductus Arteriosus, Patent; Enterocolitis, Necrotizing; Female; Humans; Indome | 2005 |
Is surgical ligation of patent ductus arteriosus necessary? The Western Australian experience of conservative management.
Topics: Cardiovascular Agents; Cause of Death; Ductus Arteriosus, Patent; Female; Gestational Age; Humans; I | 2005 |
Outcome of very low birth weight infants exposed to antenatal indomethacin for tocolysis.
Topics: Cause of Death; Cohort Studies; Critical Care; Ductus Arteriosus, Patent; Enterocolitis, Necrotizing | 2005 |
Urinary ET-1, AVP and sodium in premature infants treated with indomethacin and ibuprofen for patent ductus arteriosus.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Arginine Vasopressin; Cyclooxygenase 2 Inhibitors; Ductus A | 2005 |
Inhaled nitric oxide.
Topics: Administration, Inhalation; Anti-Inflammatory Agents, Non-Steroidal; Bronchopulmonary Dysplasia; Dev | 2005 |
New insights into spontaneous intestinal perforation using a national data set: (1) SIP is associated with early indomethacin exposure.
Topics: Analysis of Variance; Anti-Inflammatory Agents, Non-Steroidal; Cohort Studies; Databases, Factual; E | 2006 |
Effectiveness and side effects of an escalating, stepwise approach to indomethacin treatment for symptomatic patent ductus arteriosus in premature infants below 33 weeks of gestation.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Ductus Arteriosus, Patent; Humans; Indomethacin; Infant, Ne | 2005 |
Consequences of delayed surgical closure of patent ductus arteriosus in very premature infants.
Topics: Combined Modality Therapy; Ductus Arteriosus, Patent; Enteral Nutrition; Female; Gestational Age; Hu | 2006 |
Prolonged indomethacin exposure is associated with decreased white matter injury detected with magnetic resonance imaging in premature newborns at 24 to 28 weeks' gestation at birth.
Topics: Brain; Brain Damage, Chronic; Cyclooxygenase Inhibitors; Ductus Arteriosus, Patent; Gestational Age; | 2006 |
High-dose indomethacin for patent ductus arteriosus closure: how strong is the evidence?
Topics: Ductus Arteriosus, Patent; Humans; Indomethacin; Infant, Newborn; Infant, Premature; Infant, Prematu | 2006 |
Concurrent use of indomethacin and dexamethasone increases the risk of spontaneous intestinal perforation in very low birth weight neonates.
Topics: Case-Control Studies; Dexamethasone; Ductus Arteriosus, Patent; Female; Humans; Hypotension; Indomet | 2006 |
Does patent ductus arteriosus affect feed tolerance in preterm neonates?
Topics: Age Factors; Analysis of Variance; Cardiovascular Agents; Ductus Arteriosus, Patent; Enteral Nutriti | 2007 |
Effect of indomethacin on closure of ductus arteriosus in very-low-birthweight neonates.
Topics: Cardiovascular Agents; Ductus Arteriosus, Patent; Female; Humans; Indomethacin; Infant, Newborn; Inf | 2006 |
Prevention of necrotizing enterocolitis in preterm infants: a 20-year experience.
Topics: Dexamethasone; Enterocolitis, Necrotizing; Feeding Methods; Female; Humans; Indomethacin; Infant, Ex | 2007 |
Gastrointestinal perforation in very low-birthweight infants.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Diagnosis, Differential; Enterocolitis, Necrotizing; Female | 2006 |
Indomethacin prophylaxis or expectant treatment of patent ductus arteriosus in extremely low birth weight infants?
Topics: Cerebral Hemorrhage; Comorbidity; Ductus Arteriosus, Patent; Female; Humans; Indomethacin; Infant, N | 2007 |
Oral ibuprofen in early curative closure of patent ductus arteriosus in very premature infants.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Ductus Arteriosus, Patent; Echocardiography, Doppler, Color | 2007 |
Multiple courses of indomethacin and neonatal outcomes in premature infants.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Combined Modality Therapy; Ductus Arteriosus, Patent; Human | 2008 |
A third course of indomethacin.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Ductus Arteriosus, Patent; Humans; Indomethacin; Infant, Ne | 2008 |
Indomethacin therapy for patent ductus arteriosus in premature infants.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Ductus Arteriosus, Patent; Gestational Age; Humans; Indomet | 2008 |
Spontaneous closure of the patent ductus arteriosus in very low birth weight infants following discharge from the neonatal unit.
Topics: Cardiac Catheterization; Cardiovascular Agents; Ductus Arteriosus, Patent; Electrocardiography; Epid | 2009 |
[Indomethacin for closure of persisting ductus arteriosus in the premature infant].
Topics: Ductus Arteriosus, Patent; Humans; Indomethacin; Infant, Newborn; Infant, Premature, Diseases; Prost | 1981 |
Evaluation of adverse renal reactions to prolonged indomethacin therapy in preterm infants with persistent ductus arteriosus.
Topics: Blood Volume; Body Weight; Ductus Arteriosus, Patent; Humans; Indomethacin; Infant, Newborn; Infant, | 1983 |
A variant of Bartter's syndrome. Bartter's syndrome associated with hydramnios, prematurity, hypercalciuria and nephrocalcinosis.
Topics: Bartter Syndrome; Calcium; Child, Preschool; Female; Humans; Hyperaldosteronism; Indomethacin; Infan | 1984 |
Pharmacokinetics and clinical efficacy of indomethacin in premature infants with patent ductus arteriosus.
Topics: Ductus Arteriosus, Patent; Female; Humans; Indomethacin; Infant, Newborn; Infant, Premature, Disease | 1984 |
Digoxin and indomethacin in preterm infants with PDA.
Topics: Digoxin; Ductus Arteriosus, Patent; Humans; Indomethacin; Infant, Newborn; Infant, Premature, Diseas | 1984 |
Management of the premature infant with a patent ductus arteriosus.
Topics: Blood Transfusion; Cardiac Catheterization; Digoxin; Diuresis; Ductus Arteriosus, Patent; Echocardio | 1984 |
Combined noninvasive assessment of the patent ductus arteriosus in the preterm infant before and after indomethacin treatment.
Topics: Ductus Arteriosus, Patent; Echocardiography; Humans; Indomethacin; Infant, Newborn; Infant, Prematur | 1984 |
[Efficacy of indomethacin in the closure of patent ductus arteriosus in premature newborn infants with cardiac insufficiency. Analysis of 14 cases].
Topics: Birth Weight; Ductus Arteriosus, Patent; Electrocardiography; Heart Failure; Heart Murmurs; Humans; | 1984 |
[Presumed side effects of indomethacin in 2 premature infants].
Topics: Ductus Arteriosus, Patent; Female; Humans; Indomethacin; Infant, Newborn; Infant, Newborn, Diseases; | 1983 |
[Pharmacologic treatment of patent ductus arteriosus in premature infants].
Topics: Age Factors; Diuresis; Ductus Arteriosus, Patent; Humans; Indomethacin; Infant, Newborn; Infant, Pre | 1983 |
[Persistent ductus arteriosus in premature infants].
Topics: Ductus Arteriosus; Ductus Arteriosus, Patent; Humans; Indomethacin; Infant, Newborn; Infant, Prematu | 1983 |
[Indomethacin treatment of persistent ductus arteriosus in premature infants].
Topics: Ductus Arteriosus, Patent; Humans; Indomethacin; Infant, Newborn; Infant, Premature, Diseases; Respi | 1983 |
[Surgical ligation of patent ductus arteriosus in the very-low-birth-weight premature infant].
Topics: Anesthesia, General; Body Temperature; Ductus Arteriosus, Patent; Humans; Indomethacin; Infant, Low | 1983 |
Recurrence of symptomatic patent ductus arteriosus in extremely premature infants, treated with indomethacin.
Topics: Ductus Arteriosus, Patent; Echocardiography; Female; Humans; Indomethacin; Infant, Low Birth Weight; | 1984 |
Prolonged bleeding time in preterm infants receiving indomethacin for patent ductus arteriosus.
Topics: Bleeding Time; Cerebral Hemorrhage; Ductus Arteriosus, Patent; Female; Hemorrhage; Humans; Indometha | 1984 |
Patent ductus arteriosus in premature babies.
Topics: Ductus Arteriosus, Patent; Humans; Indomethacin; Infant, Newborn; Infant, Premature, Diseases | 1981 |
[Fetal hydrops following indomethacin administration during pregnancy].
Topics: Adult; Edema; Female; Humans; Indomethacin; Infant, Newborn; Infant, Premature, Diseases; Male; Mate | 1983 |
[Therapeutic problems with indomethacin in preterm infants with persistent ductus arteriosus].
Topics: Ductus Arteriosus, Patent; Humans; Indomethacin; Infant, Newborn; Infant, Premature, Diseases; Kidne | 1983 |
Indomethacin treatment in small versus large premature infants with ductus arteriosus. Comparison of plasma indomethacin concentration and clinical response.
Topics: Birth Weight; Ductus Arteriosus, Patent; Humans; Indomethacin; Infant, Newborn; Infant, Premature, D | 1983 |
[Closure of persistent ductus arteriosus in premature infants by drug therapy].
Topics: Ductus Arteriosus, Patent; Humans; Indomethacin; Infant, Newborn; Infant, Premature, Diseases; Inter | 1981 |
Early indomethacin in patent ductus of the very small premature.
Topics: Ductus Arteriosus, Patent; Humans; Indomethacin; Infant, Newborn; Infant, Premature, Diseases; Infan | 1982 |
Indomethacin and the preterm infant with a patent ductus arteriosus: relationship between plasma concentration and ductus closure.
Topics: Bacterial Infections; Dose-Response Relationship, Drug; Ductus Arteriosus, Patent; Half-Life; Humans | 1982 |
Parenteral indomethacin for closure of the patent ductus arteriosus. Clinical experience with 67 preterm infants.
Topics: Age Factors; Birth Weight; Bronchopulmonary Dysplasia; Cerebral Hemorrhage; Ductus Arteriosus, Paten | 1982 |
[Treatment of patent ductus arteriosus in preterm infants].
Topics: Digoxin; Ductus Arteriosus, Patent; Female; Furosemide; Humans; Indomethacin; Infant, Low Birth Weig | 1982 |
Patent ductus arteriosus in premature infants: a review of current management.
Topics: Ductus Arteriosus, Patent; Heart Failure; Humans; Indomethacin; Infant, Newborn; Infant, Premature, | 1982 |
[An alternative in the management of patent ductus arteriosus using indomethacin in premature newborn infants].
Topics: Birth Weight; Ductus Arteriosus, Patent; Gestational Age; Humans; Indomethacin; Infant, Newborn; Inf | 1982 |
[Maternal treatment with indomethacin and severe neonatal pulmonary hypertension (author's transl)].
Topics: Female; Humans; Hypertension, Pulmonary; Indomethacin; Infant, Newborn; Infant, Premature, Diseases; | 1981 |
Serum indomethacin concentrations after intravenous administration to preterm infants with patent ductus arteriosus.
Topics: Ductus Arteriosus, Patent; Half-Life; Humans; Indomethacin; Infant, Newborn; Infant, Premature, Dise | 1981 |
Gastrointestinal perforation following indomethacin therapy in very low birth weight infants.
Topics: Ductus Arteriosus, Patent; Female; Humans; Indomethacin; Infant, Newborn; Infant, Premature, Disease | 1981 |
A comparison of oral and intravenous indomethacin dispositions in the premature infant with patent ductus arteriosus.
Topics: Administration, Oral; Biological Availability; Ductus Arteriosus, Patent; Humans; Indomethacin; Infa | 1981 |
Inulin clearance in the premature infant receiving indomethacin.
Topics: Ductus Arteriosus, Patent; Glomerular Filtration Rate; Humans; Indomethacin; Infant, Newborn; Infant | 1980 |
[Salt and water retention after the administration of indomethacin to premature infants].
Topics: Humans; Indomethacin; Infant, Newborn; Infant, Premature, Diseases; Male; Water-Electrolyte Imbalanc | 1980 |
Plasma indomethacin levels in preterm newborns with symptomatic patent ductus arteriosus: clinical and echocardiographic assessments of response.
Topics: Ductus Arteriosus, Patent; Echocardiography; Humans; Indomethacin; Infant, Newborn; Infant, Prematur | 1980 |
Gastric perforation associated with indomethacin therapy in a pre-term infant.
Topics: Ductus Arteriosus, Patent; Female; Humans; Indomethacin; Infant, Newborn; Infant, Premature; Infant, | 1980 |
Effectiveness and pharmacokinetics of indomethacin in premature newborns with patent ductus arteriosus.
Topics: Ductus Arteriosus, Patent; Half-Life; Humans; Indomethacin; Infant, Newborn; Infant, Premature, Dise | 1980 |
Pharmacological closure of ductus arteriosus in preterm infants using indomethacin.
Topics: Ductus Arteriosus, Patent; Humans; Indomethacin; Infant, Low Birth Weight; Infant, Newborn; Infant, | 1980 |
Patent ductus arteriosus in preterm infants.
Topics: Ductus Arteriosus, Patent; Heart Failure; Humans; Hyaline Membrane Disease; Indomethacin; Infant, Ne | 1980 |
Use of indomethacin and its relationship to retinopathy of prematurity in very low birthweight infants.
Topics: Ductus Arteriosus, Patent; Humans; Indomethacin; Infant, Low Birth Weight; Infant, Newborn; Infant, | 1980 |
The disposition of indomethacin in preterm babies.
Topics: Age Factors; Ductus Arteriosus, Patent; Female; Half-Life; Humans; Indomethacin; Infant, Newborn; In | 1980 |
Pharmacokinetics of intravenously administered indomethacin in premature infants.
Topics: Double-Blind Method; Ductus Arteriosus, Patent; Half-Life; Humans; Indomethacin; Infant, Newborn; In | 1980 |
Ibuprofen treatment of patent ductus arteriosus.
Topics: Brain; Cerebrovascular Circulation; Ductus Arteriosus, Patent; Gestational Age; Humans; Ibuprofen; I | 1995 |
Predicting oliguria following indomethacin for treatment of patent ductus arteriosus.
Topics: Creatinine; Ductus Arteriosus, Patent; Humans; Indomethacin; Infant, Newborn; Infant, Premature, Dis | 1994 |
Indomethacin as a tocolytic agent: the controversy continues.
Topics: Female; Humans; Indomethacin; Infant, Newborn; Infant, Premature, Diseases; Obstetric Labor, Prematu | 1994 |
[Care of a premature infant in indomethacin therapy with an open ductus arteriosus].
Topics: Ductus Arteriosus, Patent; Humans; Indomethacin; Infant, Newborn; Infant, Premature, Diseases | 1994 |
Neonatal complications after the administration of indomethacin for preterm labor.
Topics: Cerebral Hemorrhage; Ductus Arteriosus, Patent; Enterocolitis, Pseudomembranous; Female; Fetus; Huma | 1993 |
Tocolysis with indomethacin increases the incidence of necrotizing enterocolitis in the low-birth-weight neonate.
Topics: Birth Weight; Chi-Square Distribution; Cohort Studies; Enterocolitis, Pseudomembranous; Female; Gest | 1994 |
Optimal management of patent ductus arteriosus in the neonate weighing less than 800 g.
Topics: Ductus Arteriosus, Patent; Humans; Indomethacin; Infant, Low Birth Weight; Infant, Newborn; Infant, | 1993 |
Indomethacin and apnea of prematurity.
Topics: Aminophylline; Apnea; Humans; Indomethacin; Infant, Newborn; Infant, Premature; Infant, Premature, D | 1993 |
Renal failure in two preterm infants: toxic effect of prenatal maternal indomethacin treatment?
Topics: Acute Kidney Injury; Adult; Amniocentesis; Cesarean Section; Female; Humans; Indomethacin; Infant, N | 1993 |
Criteria for use of indomethacin injection in neonates.
Topics: Ductus Arteriosus, Patent; Humans; Indomethacin; Infant, Newborn; Infant, Premature; Infant, Prematu | 1993 |
Drug induced closure of patent ductus arteriosus.
Topics: Cyclooxygenase Inhibitors; Ductus Arteriosus, Patent; Female; Fetal Diseases; Humans; Indomethacin; | 1996 |
Effects of prophylactic low-dose indomethacin on hemodynamics in very low birth weight infants.
Topics: Analysis of Variance; Blood Flow Velocity; Cerebral Hemorrhage; Cerebrovascular Circulation; Cycloox | 1998 |
Antenatal indomethacin--adverse fetal effects confirmed.
Topics: Cerebral Hemorrhage; Ductus Arteriosus, Patent; Female; Fetal Diseases; Humans; Indomethacin; Infant | 1998 |
Surgical ligation of patent ductus arteriosus in very low birth weight infants: is it safe?
Topics: Ductus Arteriosus, Patent; Female; Humans; Indomethacin; Infant, Newborn; Infant, Premature, Disease | 1998 |
Indomethacin tocolysis increases postnatal patent ductus arteriosus severity.
Topics: Ductus Arteriosus, Patent; Female; Humans; Indomethacin; Infant, Newborn; Infant, Premature; Infant, | 1998 |
The principles and practice of evidence-based neonatology.
Topics: Adrenal Cortex Hormones; Evidence-Based Medicine; Humans; Indomethacin; Infant, Newborn; Infant, Pre | 1999 |
Indomethacin-associated bowel perforations: a study of possible risk factors.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Birth Weight; Case-Control Studies; Female; Humans; Indomet | 1999 |
Adenosine infusion in the management of a micropremi neonate with pulmonary hypertension.
Topics: Adenosine; Anti-Inflammatory Agents, Non-Steroidal; Ductus Arteriosus, Patent; Fatal Outcome; Humans | 1998 |
Incidence and outcome of a 10-fold indomethacin overdose in premature infants.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Bronchopulmonary Dysplasia; Cerebral Hemorrhage; Ductus Art | 1999 |
Indomethacin treatment decreases renal blood flow velocity in human neonates.
Topics: Birth Weight; Blood Flow Velocity; Creatinine; Cyclooxygenase Inhibitors; Ductus Arteriosus, Patent; | 1999 |
Recent indomethacin tocolysis is not associated with neonatal complications in preterm infants.
Topics: Birth Weight; Case-Control Studies; Delivery, Obstetric; Drug Administration Schedule; Female; Gesta | 1999 |
Links between early adrenal function and respiratory outcome in preterm infants: airway inflammation and patent ductus arteriosus.
Topics: Adrenal Insufficiency; Bronchoalveolar Lavage Fluid; Bronchopulmonary Dysplasia; Chronic Disease; Du | 2000 |
Perinatal indomethacin treatment and neonatal complications in preterm infants.
Topics: Cerebral Hemorrhage; Enterocolitis, Necrotizing; Female; Humans; Indomethacin; Infant, Newborn; Infa | 2000 |
Effect of patent ductus arteriosus and indomethacin treatment on serum cardiac troponin T levels in preterm infants with respiratory distress syndrome.
Topics: Cardiovascular Agents; Ductus Arteriosus, Patent; Humans; Indomethacin; Infant, Newborn; Infant, Pre | 2000 |
In partial defense of prolonged indomethacin therapy for patent ductus arteriosus.
Topics: Cardiovascular Agents; Drug Administration Schedule; Ductus Arteriosus, Patent; Humans; Indomethacin | 2000 |
Ibuprofen and patent ductus arteriosus.
Topics: Cyclooxygenase Inhibitors; Ductus Arteriosus, Patent; Humans; Ibuprofen; Indomethacin; Infant, Newbo | 2000 |
[Patent ductus arteriosus. A common clinical problem in extremely premature infants].
Topics: Cyclooxygenase Inhibitors; Ductus Arteriosus, Patent; Fluid Therapy; Humans; Incidence; Indomethacin | 2000 |
Ibuprofen versus indomethacin for closure of patent ductus arteriosus.
Topics: Cyclooxygenase Inhibitors; Ductus Arteriosus, Patent; Humans; Ibuprofen; Indomethacin; Infant, Newbo | 2001 |
Diastolic flow velocity of the left pulmonary artery of patent ductus arteriosus in preterm infants.
Topics: Blood Flow Velocity; Diastole; Ductus Arteriosus, Patent; Echocardiography, Doppler, Pulsed; Female; | 2001 |
Gastroesophageal endoscopic findings and gastrointestinal symptoms in preterm neonates with and without perinatal indomethacin exposure.
Topics: Biopsy; Case-Control Studies; Ductus Arteriosus, Patent; Endoscopy, Gastrointestinal; Enteral Nutrit | 2001 |
Neonatal acute haemorrhagic gastritis and antenatal exposure to indomethacin for tocolysis.
Topics: Adolescent; Fatal Outcome; Female; Gastric Mucosa; Gastritis; Gastrointestinal Hemorrhage; Humans; I | 2001 |
Closure of the ductus arteriosus and development of pulmonary branch stenosis in babies of less than 32 weeks gestation.
Topics: Cardiovascular Agents; Disease Progression; Ductus Arteriosus, Patent; Female; Heart Murmurs; Humans | 2001 |
Treating extremely low birthweight infants with prophylactic indomethacin. Evidence for short term benefits only.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Cardiovascular Agents; Cerebral Hemorrhage; Ductus Arterios | 2002 |
[Dopplersonographic findings in neonates with significant persistent ductus arteriosus].
Topics: Anterior Cerebral Artery; Ductus Arteriosus, Patent; Echocardiography, Doppler; Echocardiography, Do | 2002 |
Factors associated with permanent closure of the ductus arteriosus: a role for prolonged indomethacin therapy.
Topics: Cardiovascular Agents; Cohort Studies; Dose-Response Relationship, Drug; Drug Administration Schedul | 2002 |
Radiographic and echocardiographic evaluation of newborns treated with indomethacin for patent ductus arteriosus.
Topics: Diagnostic Errors; Ductus Arteriosus, Patent; Echocardiography; Female; Humans; Indomethacin; Infant | 1978 |
[Treatment of hypoxia caused by a right-lef shunt in a newborn infant (effect of indomethacin associated with distending therapy) (preliminary report)].
Topics: Arteriovenous Fistula; Ductus Arteriosus, Patent; Humans; Hypoxia; Indomethacin; Infant, Newborn; In | 1978 |
Pharmacologic treatment of patent ductus arteriosus.
Topics: Drug Evaluation; Ductus Arteriosus, Patent; Humans; Indomethacin; Infant, Newborn; Infant, Premature | 1979 |
Plasma indomethacin levels in preterm newborn infants with symptomatic patent ductus arteriosus--clinical and echocardiographic assessments of response.
Topics: Ductus Arteriosus, Patent; Echocardiography; Humans; Indomethacin; Infant, Newborn; Infant, Prematur | 1979 |
Indomethacin and renal function in premature infants with persistent patent ductus arteriosus.
Topics: Ductus Arteriosus, Patent; Glomerular Filtration Rate; Humans; Indomethacin; Infant, Newborn; Infant | 1979 |
[Closure of the ductus arteriosus by medication in low birth weight infants].
Topics: Autopsy; Ductus Arteriosus, Patent; Humans; Indomethacin; Infant, Low Birth Weight; Infant, Newborn; | 1979 |
Perinatal hazards of chronic antenatal tocolysis with indomethacin.
Topics: Adult; Female; Humans; Indomethacin; Infant, Newborn; Infant, Premature, Diseases; Obstetric Labor, | 1979 |
Medical treatment of the ductus arteriosus.
Topics: Animals; Aspirin; Coronary Circulation; Ductus Arteriosus; Ductus Arteriosus, Patent; Fetal Heart; F | 1977 |
Management of premature infants with patent ductus arteriosus.
Topics: Ductus Arteriosus, Patent; Female; Humans; Indomethacin; Infant, Newborn; Infant, Premature, Disease | 1978 |
Urinary excretion of prostaglandin E following the administration of furosemide and indomethacin to sick low-birth-weight infants.
Topics: Calcium; Drug Antagonism; Ductus Arteriosus, Patent; Female; Furosemide; Humans; Hyaline Membrane Di | 1978 |
Problem of patent ductus arteriosus in premature infants.
Topics: Animals; Aspirin; Blood Pressure; Coronary Circulation; Ductus Arteriosus, Patent; Heart Failure; He | 1978 |
Operation or indomethacin for the premature ductus.
Topics: Age Factors; Ductus Arteriosus, Patent; Follow-Up Studies; Humans; Indomethacin; Infant; Infant, New | 1978 |
Pharmacologic closure of patent ductus arteriosus in the premature infant.
Topics: Cyclooxygenase Inhibitors; Depression, Chemical; Drug Evaluation; Ductus Arteriosus, Patent; Female; | 1976 |
Commentary: new thoughts on an old problem--patent ductus arteriosus in the premature infant.
Topics: Dose-Response Relationship, Drug; Ductus Arteriosus, Patent; Humans; Indomethacin; Infant, Newborn; | 1977 |
Closure of the ductus arteriosus in premature infants by inhibition of prostaglandin synthesis.
Topics: Aspirin; Depression, Chemical; Ductus Arteriosus; Ductus Arteriosus, Patent; Female; Follow-Up Studi | 1976 |
Editorial: Patent ductus revisited.
Topics: Ductus Arteriosus, Patent; Humans; Indomethacin; Infant; Infant, Newborn; Infant, Premature, Disease | 1976 |
Preterm infants with patent ductus arteriosus: treatment with an enteral preparation of indomethacin.
Topics: Administration, Oral; Ductus Arteriosus, Patent; Enteral Nutrition; Humans; Indomethacin; Infant, Ne | 1992 |
Atrial natriuretic peptide in the diagnosis of patent ductus arteriosus.
Topics: Atrial Natriuretic Factor; Ductus Arteriosus, Patent; Female; Humans; Indomethacin; Infant, Newborn; | 1992 |
Regional cerebral blood flow velocity changes after indomethacin infusion in preterm infants.
Topics: Blood Flow Velocity; Cerebrovascular Circulation; Ductus Arteriosus, Patent; Echocardiography, Doppl | 1992 |
Therapy of symptomatic patent ductus arteriosus in preterms using mefenemic acid and indomethacin.
Topics: Ductus Arteriosus, Patent; Humans; Indomethacin; Infant, Newborn; Infant, Premature, Diseases; Mefen | 1992 |
Day case ligation of patent ductus arteriosus in preterm infants: a 10 year review.
Topics: Birth Weight; Ductus Arteriosus, Patent; Gestational Age; Humans; Indomethacin; Infant, Newborn; Inf | 1991 |
Indomethacin therapy for intraventricular hemorrhage in neonates: another use for that "old" drug.
Topics: Cerebral Hemorrhage; Cerebral Ventricles; Humans; Indomethacin; Infant, Newborn; Infant, Premature; | 1991 |
Cerebral lesions in preterm infants after tocolytic indomethacin.
Topics: Administration, Rectal; Brain; Brain Damage, Chronic; Cerebral Hemorrhage; Dose-Response Relationshi | 1990 |
Asymmetrical pulmonary changes in premature infants with surgical closure of a persistent ductus arteriosus.
Topics: Bronchopulmonary Dysplasia; Ductus Arteriosus, Patent; Humans; Hyaline Membrane Disease; Indomethaci | 1990 |
Neonatal renal dysfunction and intrauterine exposure to prostaglandin synthesis inhibitors.
Topics: Acute Kidney Injury; Anti-Inflammatory Agents, Non-Steroidal; Betamethasone; Cesarean Section; Cyclo | 1989 |
Pharmacokinetics of intra-arterial indomethacin treatment for patent ductus arteriosus.
Topics: Ductus Arteriosus, Patent; Echocardiography; Female; Humans; Indomethacin; Infant, Newborn; Infant, | 1989 |
Does the respiratory distress syndrome in twins and singletons run different risks of persistent ductus arteriosus?
Topics: Diseases in Twins; Ductus Arteriosus, Patent; Echocardiography; Humans; Indomethacin; Infant, Low Bi | 1989 |
Prostaglandin E2 in the lung lavage fluid of premature newborns before and after surgical or medical closure of a patent ductus arteriosus.
Topics: Bronchoalveolar Lavage Fluid; Dinoprostone; Ductus Arteriosus, Patent; Female; Humans; Indomethacin; | 1989 |
Localized intestinal perforation following intravenous indomethacin in premature infants.
Topics: Ductus Arteriosus, Patent; Humans; Indomethacin; Infant, Newborn; Infant, Premature, Diseases; Intes | 1989 |
[Indomethacin or ligation in the treatment of persistent ductus arteriosus: a report of clinical experiences].
Topics: Dose-Response Relationship, Drug; Ductus Arteriosus, Patent; Follow-Up Studies; Humans; Indomethacin | 1989 |
Indomethacin therapy in premature infants with patent ductus arteriosus--determination of therapeutic plasma levels.
Topics: Ductus Arteriosus, Patent; Half-Life; Humans; Indomethacin; Infant, Newborn; Infant, Premature, Dise | 1989 |
Preterm labor: its diagnosis and management.
Topics: Adolescent; Adrenergic beta-Agonists; Adult; Female; Fluid Therapy; Humans; Indomethacin; Infant, Ne | 1986 |
Sepsis and indomethacin failure in premature infants with symptomatic patent ductus arteriosus.
Topics: Bacterial Infections; Ductus Arteriosus, Patent; Humans; Indomethacin; Infant, Newborn; Infant, Prem | 1987 |
Effect of infusion rate of indomethacin on cerebrovascular responses in preterm neonates.
Topics: Blood Flow Velocity; Brain; Cerebrovascular Circulation; Drug Administration Schedule; Ductus Arteri | 1989 |
Tolerance of intravenous indomethacin treatment for premature infants with patent ductus arteriosus.
Topics: Drug Tolerance; Ductus Arteriosus, Patent; Humans; Indomethacin; Infant, Newborn; Infant, Premature, | 1988 |
Symptomatic patent ductus arteriosus in premature infants.
Topics: Cross-Sectional Studies; Ductus Arteriosus, Patent; Female; Humans; Indomethacin; Infant, Low Birth | 1988 |
Late closure of the ductus arteriosus using indomethacin in the preterm infant.
Topics: Ductus Arteriosus, Patent; Echocardiography; Female; Humans; Indomethacin; Infant, Newborn; Infant, | 1988 |
Indomethacin and cerebral blood flow in premature infants treated for patent ductus arteriosus.
Topics: Cerebrovascular Circulation; Ductus Arteriosus, Patent; Humans; Indomethacin; Infant, Newborn; Infan | 1988 |
[Disorders of kidney function and acute kidney failure in newborn infants].
Topics: Acid-Base Equilibrium; Acute Kidney Injury; Aminoglycosides; Anti-Bacterial Agents; Creatinine; Diag | 1987 |
Prolonged indomethacin treatment in preterm infants with symptomatic patent ductus arteriosus: efficacy, drug level monitoring, and patient selection.
Topics: Ductus Arteriosus, Patent; Humans; Indomethacin; Infant, Newborn; Infant, Premature, Diseases; Monit | 1987 |
[The significance of renal prostaglandins for kidney function in early childhood].
Topics: Angiotensin II; Aspirin; Child, Preschool; Creatinine; Ductus Arteriosus, Patent; Glomerular Filtrat | 1987 |
Periventricular haemorrhage: association with patent ductus arteriosus and its treatment with indomethacin or surgery.
Topics: Cerebral Hemorrhage; Cerebral Ventricles; Ductus Arteriosus, Patent; Humans; Indomethacin; Infant, N | 1987 |
Symptomatic patent ductus arteriosus in premature neonates: a 5 year study in Toa Payoh Hospital.
Topics: Ductus Arteriosus, Patent; Humans; Indomethacin; Infant, Newborn; Infant, Premature, Diseases; Respi | 1987 |
Effect of a modified fluid therapy on renal function during indomethacin therapy for persistent ductus arteriosus.
Topics: Creatinine; Fluid Therapy; Glomerular Filtration Rate; Humans; Indomethacin; Infant; Infant, Newborn | 1987 |
[Treatment with intravenous indomethacin of symptomatic ductus arteriosus in premature newborn infants].
Topics: Ductus Arteriosus, Patent; Humans; Indomethacin; Infant, Newborn; Infant, Premature, Diseases; Injec | 1987 |
The effect of indomethacin on cerebral blood-flow velocity in premature infants.
Topics: Blood Flow Velocity; Cerebrovascular Circulation; Ductus Arteriosus, Patent; Humans; Indomethacin; I | 1987 |
Obstetric management of the very low birth weight fetus.
Topics: Adrenal Cortex Hormones; Extraction, Obstetrical; Female; Fetal Distress; Fetal Monitoring; Fetal Or | 1986 |
The management of symptomatic patient ductus arteriosus in premature infants.
Topics: Ductus Arteriosus, Patent; Humans; Indomethacin; Infant, Low Birth Weight; Infant, Newborn; Infant, | 1986 |
Pharmacological manipulation of the ductus arteriosus.
Topics: Drug Administration Schedule; Ductus Arteriosus; Ductus Arteriosus, Patent; Heart Defects, Congenita | 1986 |
[Peculiarities of drug therapy in childhood].
Topics: Apnea; Biological Availability; Biotransformation; Caffeine; Child; Child, Preschool; Dexamethasone; | 1986 |
Response of the patent ductus arteriosus to indomethacin treatment.
Topics: Ductus Arteriosus, Patent; Humans; Indomethacin; Infant, Newborn; Infant, Premature, Diseases | 1987 |
Response of the patent ductus arteriosus to indomethacin treatment.
Topics: Drug Evaluation; Ductus Arteriosus, Patent; Echocardiography; Female; Humans; Indomethacin; Infant, | 1987 |
Indomethacin therapy in premature infants with patent ductus arteriosus and oliguria.
Topics: Anuria; Drug Therapy, Combination; Ductus Arteriosus, Patent; Furosemide; Humans; Indomethacin; Infa | 1986 |
Possible indomethacin-aminoglycoside interaction in preterm infants.
Topics: Amikacin; Aminoglycosides; Anti-Bacterial Agents; Creatinine; Diuresis; Drug Interactions; Ductus Ar | 1985 |
Intestinal perforation associated with indomethacin treatment in premature infants.
Topics: Ductus Arteriosus, Patent; Female; Humans; Indomethacin; Infant, Low Birth Weight; Infant, Newborn; | 1985 |
Indomethacin therapy of patent ductus in preterm infants controlled by plasma levels.
Topics: Ductus Arteriosus, Patent; Humans; Indomethacin; Infant, Newborn; Infant, Premature, Diseases | 1985 |